MeSH term
Frequency | Condition_Probility | History, 20th Century | 2 | 1.0 |
Humans | 1732 | 0.0 |
United States | 6 | 0.0 |
Female | 988 | 1.0 |
*Health Status | 2 | 5.0 |
Male | 1061 | 1.0 |
Animals | 402 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 365 | 0.0 |
Blotting, Western | 26 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Glycosylation | 5 | 0.0 |
Mice | 276 | 0.0 |
Mice, Transgenic | 181 | 6.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 26 | 0.0 |
Cholesterol/blood | 205 | 17.0 |
Combined Modality Therapy | 22 | 1.0 |
*Diet, Fat-Restricted | 4 | 21.0 |
*Estrogen Replacement Therapy | 5 | 4.0 |
Lipoproteins, HDL Cholesterol/blood | 120 | 17.0 |
Lipoproteins, LDL Cholesterol/blood | 94 | 17.0 |
Middle Aged | 769 | 1.0 |
Postmenopause | 5 | 2.0 |
Research Support, Non-U.S. Gov't | 907 | 0.0 |
Treatment Outcome | 39 | 1.0 |
Triglycerides/blood | 281 | 20.0 |
Weight Loss/physiology | 2 | 10.0 |
Adult | 781 | 1.0 |
Biological Transport/physiology | 2 | 1.0 |
Cholesterol Esters/*metabolism | 4 | 4.0 |
*Circadian Rhythm | 6 | 2.0 |
Exercise/*physiology | 18 | 4.0 |
Lipoprotein Lipase/*metabolism | 11 | 5.0 |
Lipoproteins, HDL Cholesterol/metabolism | 6 | 12.0 |
Liver/metabolism | 13 | 1.0 |
Reference Values | 80 | 1.0 |
Cohort Studies | 36 | 1.0 |
Neoplasm, Residual/*diagnosis | 4 | 9.0 |
Recombinant Proteins/diagnostic use | 11 | 50.0 |
Risk Factors | 110 | 1.0 |
Thyroglobulin/*blood | 169 | 97.0 |
Thyroid Neoplasms/*diagnosis | 6 | 50.0 |
Thyrotropin/*diagnostic use | 16 | 94.0 |
Aged | 436 | 1.0 |
Carcinoma, Papillary/blood/therapy | 2 | 100.0 |
Child | 129 | 0.0 |
Population Surveillance | 3 | 1.0 |
Predictive Value of Tests | 32 | 1.0 |
RNA, Messenger/*blood | 7 | 19.0 |
Remission Induction | 2 | 0.0 |
Thyroid Neoplasms/*blood/*therapy | 2 | 100.0 |
Antigens, CD4/genetics | 2 | 3.0 |
Apoptosis | 4 | 0.0 |
Heart/physiopathology | 2 | 5.0 |
Mutation | 27 | 0.0 |
Myocardium/metabolism | 4 | 1.0 |
Cell Death/genetics | 2 | 5.0 |
*Gene Therapy | 5 | 1.0 |
Gene Transfer Techniques | 6 | 1.0 |
Genetic Vectors | 4 | 0.0 |
Amino Acid Substitution | 8 | 0.0 |
Animals, Genetically Modified | 2 | 0.0 |
Base Sequence | 53 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Molecular Sequence Data | 61 | 0.0 |
Myocardium/*metabolism | 4 | 1.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Comorbidity | 4 | 1.0 |
*Disease Models, Animal | 11 | 3.0 |
Disease Progression | 16 | 0.0 |
Antilipemic Agents/*therapeutic use | 21 | 28.0 |
Diabetes Mellitus/blood | 4 | 5.0 |
Diabetes Mellitus, Type 2/*blood/complications | 3 | 15.0 |
English Abstract | 174 | 1.0 |
Lipoproteins, HDL Cholesterol/blood/*drug effects | 3 | 75.0 |
Lipoproteins, LDL Cholesterol/blood/*drug effects | 2 | 33.0 |
Obesity | 5 | 8.0 |
Retrospective Studies | 46 | 1.0 |
Simvastatin/*therapeutic use | 4 | 17.0 |
Comparative Study | 284 | 1.0 |
Exercise | 4 | 3.0 |
Patient Compliance | 3 | 1.0 |
Probability | 10 | 1.0 |
Risk Assessment | 8 | 0.0 |
Sampling Studies | 4 | 2.0 |
Sensitivity and Specificity | 61 | 1.0 |
*Weight Loss | 2 | 4.0 |
Autoantibodies/blood | 11 | 6.0 |
Cross Reactions | 23 | 2.0 |
Immunoassay/*methods | 3 | 3.0 |
Immunoradiometric Assay | 13 | 12.0 |
Reproducibility of Results | 24 | 1.0 |
Thyroglobulin/*blood/immunology | 19 | 100.0 |
Thyroid Neoplasms/diagnosis | 6 | 85.0 |
Thyroiditis, Autoimmune/diagnosis | 3 | 75.0 |
Thyrotropin/blood | 67 | 16.0 |
Anticholesteremic Agents/*therapeutic use | 4 | 7.0 |
Apolipoproteins/blood | 27 | 11.0 |
Blood Glucose/metabolism | 46 | 6.0 |
Cholesterol/*blood | 59 | 24.0 |
Diabetes Mellitus, Type 2/blood/complications/*drug therapy | 2 | 33.0 |
Drug Therapy, Combination | 20 | 1.0 |
Fibrinogen/metabolism | 5 | 2.0 |
Heptanoic Acids/*therapeutic use | 4 | 16.0 |
Hyperlipidemia/complications/*drug therapy | 2 | 100.0 |
Lipoprotein(a)/blood | 10 | 15.0 |
Lipoproteins, HDL/blood | 51 | 19.0 |
Procetofen/*therapeutic use | 7 | 43.0 |
Pyrroles/*therapeutic use | 4 | 10.0 |
Adolescent | 244 | 1.0 |
Genetic Markers | 6 | 0.0 |
Globins/*genetics | 2 | 1.0 |
*Polymorphism, Genetic | 32 | 0.0 |
Promoter Regions (Genetics) | 19 | 0.0 |
Body Composition | 13 | 5.0 |
Insulin Resistance/*physiology | 11 | 14.0 |
Postprandial Period/*physiology | 7 | 21.0 |
Severity of Illness Index | 11 | 0.0 |
Triglycerides/*blood | 193 | 52.0 |
Carrier Proteins/*genetics | 7 | 0.0 |
Case-Control Studies | 46 | 0.0 |
Cell Line | 32 | 0.0 |
DNA | 2 | 0.0 |
Diabetes Mellitus, Type 2/blood | 4 | 11.0 |
*Promoter Regions (Genetics) | 10 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Cytokines/biosynthesis | 2 | 0.0 |
Immunity, Natural/genetics | 2 | 3.0 |
Lymphocyte Activation/*immunology | 3 | 0.0 |
Mice, Inbred C57BL | 53 | 1.0 |
Mice, Inbred ICR | 2 | 0.0 |
*Protein Biosynthesis | 3 | 0.0 |
*Proteins | 2 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/biosynthesis | 2 | 9.0 |
Hypertriglyceridemia/*blood/chemically induced | 2 | 100.0 |
Pregnancy | 32 | 0.0 |
Rats | 67 | 0.0 |
Rats, Sprague-Dawley | 14 | 0.0 |
Area Under Curve | 8 | 1.0 |
Blood Glucose/analysis | 34 | 5.0 |
Diabetes Mellitus, Type 2/*blood | 13 | 11.0 |
Fasting | 39 | 12.0 |
Glucose Tolerance Test | 34 | 8.0 |
Hypertriglyceridemia/*blood | 18 | 46.0 |
Lipoproteins, VLDL/*blood | 22 | 30.0 |
Postprandial Period | 27 | 30.0 |
Apolipoproteins C/*genetics | 7 | 7.0 |
Asian Continental Ancestry Group/genetics | 6 | 1.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Genotype | 51 | 0.0 |
Polymorphism, Genetic/*genetics | 5 | 0.0 |
Aged, 80 and over | 78 | 0.0 |
Body Mass Index | 63 | 6.0 |
Fasting/blood | 8 | 14.0 |
*Intercellular Signaling Peptides and Proteins | 6 | 1.0 |
Osmolar Concentration | 15 | 2.0 |
Proteins/*analysis | 3 | 2.0 |
Dietary Fats | 5 | 13.0 |
*Exercise | 8 | 5.0 |
*Life Style | 3 | 5.0 |
Skinfold Thickness | 4 | 5.0 |
Sports | 3 | 23.0 |
Apolipoproteins E/*genetics | 14 | 1.0 |
Gene Frequency | 34 | 0.0 |
Lipids/blood/genetics | 2 | 50.0 |
Lipoprotein Lipase/*genetics | 20 | 11.0 |
*Mutation | 15 | 0.0 |
Phenotype | 56 | 0.0 |
Procetofen/administration & dosage/*therapeutic use | 2 | 66.0 |
Transcription Factors/*genetics | 5 | 0.0 |
Triglycerides/blood/genetics | 2 | 25.0 |
Amyloid beta-Protein/*metabolism | 3 | 3.0 |
Behavior, Animal/*physiology | 2 | 7.0 |
Brain/metabolism | 2 | 0.0 |
Disease Models, Animal | 48 | 2.0 |
Gene Expression | 31 | 0.0 |
Immunohistochemistry | 46 | 0.0 |
Maze Learning/physiology | 2 | 12.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Prostaglandin-Endoperoxide Synthase/*metabolism | 2 | 3.0 |
Antibodies/immunology | 5 | 1.0 |
Quality Control | 4 | 2.0 |
Arthritis, Rheumatoid/*immunology | 4 | 1.0 |
Autoantibodies/*analysis | 18 | 8.0 |
Prognosis | 32 | 0.0 |
Thyroid Diseases/*immunology | 4 | 13.0 |
Thyroiditis, Autoimmune/etiology/*immunology | 2 | 40.0 |
RNA, Messenger/genetics | 6 | 0.0 |
Thyroid Gland/*metabolism | 13 | 31.0 |
Life Style | 8 | 6.0 |
Lipids/*blood | 121 | 21.0 |
Regression Analysis | 53 | 3.0 |
Body Weight | 38 | 5.0 |
Kinetics | 56 | 0.0 |
Lethal Dose 50 | 2 | 3.0 |
Lung/pathology | 2 | 2.0 |
Linoleic Acid/*administration & dosage/chemistry | 2 | 100.0 |
Questionnaires | 8 | 1.0 |
Triglycerides/blood/*chemistry | 2 | 100.0 |
Lipids/blood | 65 | 10.0 |
Lipoproteins/blood | 54 | 13.0 |
Particle Size | 34 | 12.0 |
Cell Division | 8 | 0.0 |
Cells, Cultured | 67 | 0.0 |
Echocardiography | 4 | 1.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Mitosis | 2 | 0.0 |
Organ Size | 11 | 5.0 |
Precipitin Tests | 6 | 0.0 |
Protein Binding | 9 | 0.0 |
Time Factors | 100 | 0.0 |
Body Weight/drug effects | 3 | 1.0 |
Gene Expression Regulation | 13 | 0.0 |
Hyperlipidemia/blood/*genetics | 2 | 25.0 |
Insulin Resistance | 17 | 10.0 |
Apolipoproteins B/blood | 39 | 15.0 |
Apolipoproteins C/blood | 7 | 24.0 |
Apolipoproteins E/blood | 10 | 21.0 |
Hyperlipidemia/*drug therapy | 7 | 24.0 |
Alleles | 39 | 0.0 |
Cholesterol Esters/*blood | 3 | 3.0 |
Coronary Angiography | 5 | 2.0 |
Data Interpretation, Statistical | 4 | 1.0 |
Antibodies, Anti-Idiotypic/*immunology | 3 | 6.0 |
Plasmids | 5 | 0.0 |
Tumor Markers, Biological | 2 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
Carrier Proteins/*pharmacology | 2 | 4.0 |
Enzyme-Linked Immunosorbent Assay | 33 | 0.0 |
Survival Analysis | 18 | 0.0 |
Double-Blind Method | 45 | 2.0 |
Drug Evaluation | 3 | 1.0 |
Follow-Up Studies | 88 | 2.0 |
Gemfibrozil/*therapeutic use | 13 | 52.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use | 8 | 17.0 |
Lipoproteins, LDL Cholesterol/drug effects | 2 | 66.0 |
Pravastatin/*therapeutic use | 2 | 14.0 |
Insulin/blood | 61 | 9.0 |
Insulin-Like Growth Factor I/*metabolism | 3 | 2.0 |
Lipoproteins/*blood | 94 | 15.0 |
Lipoproteins, LDL/blood | 43 | 18.0 |
Endothelial Growth Factors/*blood | 2 | 0.0 |
Lymphokines/*blood | 2 | 0.0 |
Thyrotropin/*pharmacology | 5 | 17.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Antibodies/*blood | 4 | 8.0 |
Autoantibodies/analysis | 16 | 9.0 |
Chronic Disease | 14 | 0.0 |
Iodide Peroxidase/*immunology | 11 | 14.0 |
Prospective Studies | 51 | 1.0 |
Thyroglobulin/immunology | 19 | 34.0 |
Thyroid Gland/ultrasonography | 3 | 50.0 |
*Gamma Cameras | 2 | 100.0 |
Iodine Radioisotopes/*therapeutic use | 13 | 44.0 |
Neoplasm Metastasis | 24 | 2.0 |
Radiopharmaceuticals/*therapeutic use | 2 | 66.0 |
Thyroglobulin/*analysis | 17 | 77.0 |
Thyroid Neoplasms/*radionuclide imaging/radiotherapy | 2 | 66.0 |
Iodine Radioisotopes/*diagnostic use/pharmacokinetics | 2 | 25.0 |
Neoplasm Recurrence, Local/diagnosis | 10 | 32.0 |
Postoperative Period | 16 | 5.0 |
Radiopharmaceuticals/*diagnostic use/pharmacokinetics | 2 | 16.0 |
Thyroglobulin/analysis | 15 | 65.0 |
Thyroid Hormones/therapeutic use | 6 | 66.0 |
Thyroidectomy | 70 | 53.0 |
Diabetes Mellitus/genetics | 2 | 5.0 |
Diabetic Nephropathies/*genetics | 2 | 8.0 |
Exons | 9 | 0.0 |
*Gene Frequency | 4 | 0.0 |
Introns | 7 | 0.0 |
Point Mutation | 8 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 3 | 0.0 |
HIV-1/*physiology | 2 | 0.0 |
In Situ Hybridization | 12 | 0.0 |
Mice, Inbred C3H | 12 | 1.0 |
Mice, Inbred DBA | 10 | 3.0 |
Iodine Radioisotopes/therapeutic use | 21 | 52.0 |
Logistic Models | 10 | 1.0 |
Neoplasm Metastasis/*diagnosis | 4 | 26.0 |
*Thyroidectomy | 16 | 61.0 |
Thyroxine/therapeutic use | 23 | 67.0 |
Binding Sites | 18 | 0.0 |
DNA/genetics | 5 | 0.0 |
DNA Mutational Analysis | 2 | 0.0 |
Muscle, Skeletal/*enzymology | 2 | 4.0 |
Triglycerides/blood/*metabolism | 7 | 38.0 |
CD8-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Gene Products, nef/genetics/*metabolism | 2 | 6.0 |
*Genes, nef | 2 | 6.0 |
Hyperlipoproteinemia/blood | 2 | 25.0 |
Lipoproteins, HDL Cholesterol/*blood | 41 | 18.0 |
Lipoproteins, LDL Cholesterol/*blood | 17 | 20.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 55 | 0.0 |
Incidence | 4 | 0.0 |
Pregnancy/*physiology | 3 | 6.0 |
Pregnancy Trimester, First | 2 | 0.0 |
Pregnancy Trimester, Second | 3 | 1.0 |
Pregnancy Trimester, Third | 4 | 2.0 |
Asian Continental Ancestry Group/*genetics | 4 | 1.0 |
*Glycoproteins | 18 | 2.0 |
Japan | 13 | 0.0 |
Multivariate Analysis | 13 | 0.0 |
Analysis of Variance | 43 | 2.0 |
Apolipoprotein A-I/*metabolism | 4 | 9.0 |
China/epidemiology | 5 | 3.0 |
Lipoproteins, HDL Cholesterol/*blood/genetics | 2 | 25.0 |
Liver/enzymology/metabolism | 2 | 6.0 |
Polymerase Chain Reaction | 37 | 0.0 |
Sex Factors | 38 | 2.0 |
Apolipoproteins B/*metabolism | 7 | 7.0 |
Hyperlipidemia/etiology | 3 | 42.0 |
Metabolic Syndrome X/complications/*metabolism | 2 | 100.0 |
Models, Biological | 11 | 0.0 |
Chemotherapy, Adjuvant | 3 | 1.0 |
Lipoproteins/blood/*drug effects | 3 | 30.0 |
Iodine Radioisotopes/diagnostic use | 34 | 11.0 |
Neoplasm Recurrence, Local/blood/*diagnosis/radionuclide imaging | 2 | 100.0 |
Thyroid Neoplasms/blood/*diagnosis/radionuclide imaging | 2 | 100.0 |
Whole-Body Counting | 11 | 61.0 |
Amino Acid Sequence | 42 | 0.0 |
Models, Molecular | 2 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Hypercholesterolemia/blood/*diet therapy | 2 | 40.0 |
Abdomen | 7 | 8.0 |
*Adipose Tissue | 4 | 11.0 |
Anthropometry | 10 | 4.0 |
Pilot Projects | 6 | 0.0 |
ROC Curve | 4 | 2.0 |
Apolipoproteins B/*blood | 16 | 10.0 |
Kidney Failure/*blood | 2 | 40.0 |
Linear Models | 6 | 1.0 |
Reagent Kits, Diagnostic | 7 | 4.0 |
Renal Dialysis | 7 | 2.0 |
Apolipoproteins B/*genetics | 4 | 2.0 |
Biological Transport | 12 | 0.0 |
Blotting, Northern | 10 | 0.0 |
Cholesterol/metabolism | 5 | 1.0 |
Chromatography, High Pressure Liquid | 18 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 30 | 0.0 |
Lipids/metabolism | 13 | 4.0 |
Lipoproteins/metabolism | 3 | 2.0 |
Models, Genetic | 4 | 0.0 |
RNA/metabolism | 3 | 0.0 |
RNA, Messenger/metabolism | 16 | 0.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Algorithms | 2 | 0.0 |
Iodine Radioisotopes/*diagnostic use | 16 | 27.0 |
Thyroid Neoplasms/blood/*radionuclide imaging | 4 | 100.0 |
*Whole-Body Counting | 2 | 100.0 |
Alternative Splicing | 4 | 0.0 |
Computer Systems | 2 | 3.0 |
RNA, Messenger/*blood/genetics | 3 | 27.0 |
Thyroglobulin/blood/*genetics | 5 | 100.0 |
Thyroid Neoplasms/blood/*genetics/surgery | 2 | 100.0 |
Peptides/blood | 2 | 5.0 |
Singapore | 2 | 4.0 |
Dietary Fats/metabolism | 4 | 12.0 |
Fasting/physiology | 2 | 12.0 |
Insulin/*blood | 13 | 7.0 |
Postprandial Period/physiology | 2 | 11.0 |
*African Continental Ancestry Group | 7 | 6.0 |
Dietary Fats/*administration & dosage | 15 | 18.0 |
*European Continental Ancestry Group | 2 | 2.0 |
Lipolysis | 8 | 9.0 |
*Postprandial Period | 10 | 34.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
RNA, Messenger/*metabolism | 4 | 0.0 |
China | 5 | 1.0 |
Iodide Peroxidase/metabolism | 2 | 16.0 |
Rural Population | 4 | 4.0 |
Thyroglobulin/metabolism | 13 | 50.0 |
Thyroid Function Tests | 21 | 25.0 |
Alzheimer Disease/*genetics | 3 | 0.0 |
Cerebral Cortex/metabolism | 2 | 3.0 |
Hippocampus/metabolism | 3 | 3.0 |
Behavior, Animal | 3 | 4.0 |
Glial Fibrillary Acidic Protein/metabolism | 4 | 1.0 |
Lipid Peroxidation | 6 | 5.0 |
Motor Activity | 4 | 8.0 |
Reaction Time | 2 | 1.0 |
Aging/physiology | 3 | 1.0 |
Apolipoproteins E/metabolism | 3 | 4.0 |
Safety | 3 | 2.0 |
Iodide Peroxidase/immunology | 15 | 27.0 |
Brain/*pathology | 2 | 1.0 |
Apoptosis/physiology | 2 | 0.0 |
Carrier Proteins/metabolism | 4 | 0.0 |
Enzyme Inhibitors/pharmacology | 11 | 0.0 |
Signal Transduction/physiology | 2 | 0.0 |
Superoxide Dismutase/*biosynthesis/genetics | 3 | 16.0 |
Superoxides/metabolism | 2 | 0.0 |
Cell Count | 2 | 0.0 |
Congo Red | 2 | 13.0 |
Dyes | 3 | 2.0 |
In Vitro | 29 | 0.0 |
Phosphorylation | 7 | 0.0 |
Solubility | 6 | 0.0 |
tau Proteins/chemistry/genetics/*metabolism | 2 | 33.0 |
Cytokines/*biosynthesis | 2 | 0.0 |
Immunoenzyme Techniques | 16 | 0.0 |
Leukocyte Count | 7 | 0.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
*Receptors, Immunologic | 4 | 2.0 |
Up-Regulation | 5 | 0.0 |
Autoantibodies/*blood | 22 | 8.0 |
Graves' Disease/*blood | 3 | 50.0 |
Immunoradiometric Assay/methods | 2 | 14.0 |
Brain Ischemia/metabolism | 2 | 25.0 |
Ca(2+)-Transporting ATPase/antagonists & inhibitors | 4 | 25.0 |
Calcium/*metabolism | 11 | 1.0 |
Cytosol/metabolism | 2 | 0.0 |
Endoplasmic Reticulum/metabolism | 4 | 1.0 |
Hydroquinones/pharmacology | 2 | 6.0 |
Thapsigargin/pharmacology | 9 | 8.0 |
Tumor Cells, Cultured | 35 | 0.0 |
Myocardial Ischemia/blood/*epidemiology | 2 | 100.0 |
Proportional Hazards Models | 4 | 0.0 |
Quebec/epidemiology | 2 | 6.0 |
Dimerization | 2 | 0.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Mutation, Missense | 4 | 0.0 |
Immunoassay | 4 | 1.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Thyroid Neoplasms/*pathology | 7 | 35.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Energy Intake | 4 | 2.0 |
Hemoglobin A, Glycosylated/analysis | 13 | 2.0 |
Recombinant Proteins/pharmacology | 8 | 0.0 |
Thyrotropin/blood/*pharmacology | 2 | 100.0 |
Oxidation-Reduction | 21 | 1.0 |
Peptide Fragments/immunology/*metabolism | 2 | 15.0 |
Thyroglobulin/*metabolism | 15 | 78.0 |
Thyroid Gland/drug effects/*metabolism | 4 | 36.0 |
Thyroiditis, Autoimmune/*immunology | 28 | 35.0 |
Cross-Sectional Studies | 26 | 2.0 |
Energy Metabolism/physiology | 4 | 6.0 |
Evaluation Studies | 8 | 1.0 |
Hyperlipidemia/blood | 8 | 21.0 |
Hypertriglyceridemia/blood | 5 | 20.0 |
Lipids/*blood/chemistry | 4 | 66.0 |
Lipoproteins, LDL/*blood | 25 | 15.0 |
Obesity/blood | 6 | 17.0 |
Down-Regulation | 7 | 0.0 |
Injections, Intramuscular | 3 | 1.0 |
Lipids/blood/metabolism | 3 | 27.0 |
Flow Cytometry | 5 | 0.0 |
Lymphocyte Activation | 16 | 0.0 |
Sequence Deletion | 6 | 0.0 |
Aging | 6 | 1.0 |
Apolipoproteins A/*blood | 3 | 6.0 |
Biological Markers | 12 | 0.0 |
Body Constitution | 4 | 2.0 |
Dietary Fats/pharmacology | 7 | 20.0 |
Obesity/*blood | 6 | 7.0 |
Sex Characteristics | 9 | 1.0 |
Abdomen/*pathology | 2 | 40.0 |
Lipoproteins, HDL/*chemistry/*metabolism | 2 | 40.0 |
Polymorphism, Genetic | 21 | 0.0 |
Hypoglycemic Agents/*pharmacology | 2 | 4.0 |
Receptors, Cytoplasmic and Nuclear/*antagonists & inhibitors/genetics | 2 | 66.0 |
Transcription Factors/*antagonists & inhibitors/genetics | 2 | 22.0 |
Apolipoproteins B/metabolism | 4 | 4.0 |
Cross-Over Studies | 18 | 2.0 |
Lipoprotein Lipase/*blood | 4 | 3.0 |
Administration, Oral | 17 | 1.0 |
Apolipoproteins E/blood/*genetics | 7 | 10.0 |
*Hormone Replacement Therapy | 3 | 8.0 |
Spain | 2 | 0.0 |
Brain/drug effects/pathology | 2 | 28.0 |
Cell Death | 4 | 1.0 |
Mice, Transgenic/genetics | 8 | 14.0 |
*Sex Characteristics | 7 | 4.0 |
Staining and Labeling | 6 | 0.0 |
Cholesterol Esters/blood | 14 | 11.0 |
Coronary Disease/genetics | 5 | 14.0 |
Esterification | 7 | 8.0 |
Genetic Predisposition to Disease | 12 | 0.0 |
Gestational Age | 5 | 0.0 |
Heterozygote | 18 | 0.0 |
Hypertriglyceridemia/*genetics | 4 | 33.0 |
Lipoprotein Lipase/*genetics/metabolism | 3 | 9.0 |
Weight Gain | 2 | 3.0 |
Adipocytes/cytology | 2 | 16.0 |
Cell Differentiation | 11 | 0.0 |
*Insulin Resistance | 22 | 11.0 |
Proteins/metabolism | 5 | 0.0 |
Retinoid X Receptors | 4 | 1.0 |
Triglycerides/metabolism | 24 | 14.0 |
Carrier Proteins/*metabolism | 6 | 0.0 |
Lipids/*metabolism | 23 | 9.0 |
Triazenes/pharmacology | 2 | 33.0 |
Hyperinsulinism/*blood | 2 | 11.0 |
Variation (Genetics) | 9 | 0.0 |
Antilipemic Agents/therapeutic use | 7 | 24.0 |
Bezafibrate/therapeutic use | 4 | 57.0 |
Biological Markers/blood | 23 | 1.0 |
Gemfibrozil/therapeutic use | 4 | 50.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use | 3 | 9.0 |
Lipoproteins, HDL/*blood | 24 | 12.0 |
Randomized Controlled Trials | 5 | 1.0 |
Deoxyglucose/pharmacokinetics | 2 | 22.0 |
Glucose/*metabolism | 2 | 1.0 |
Insulin/*physiology | 4 | 8.0 |
Triglycerides/*metabolism | 18 | 21.0 |
Iodine Radioisotopes/*diagnostic use/therapeutic use | 7 | 100.0 |
Neoplasm Recurrence, Local/*radionuclide imaging | 2 | 50.0 |
Thyroglobulin/blood | 57 | 86.0 |
Thyroid Neoplasms/blood/*radionuclide imaging/radiotherapy | 3 | 100.0 |
Fetal Blood/chemistry | 4 | 7.0 |
Hypothyroidism/blood/*physiopathology | 2 | 28.0 |
Infant, Newborn/blood/*physiology | 2 | 100.0 |
Iodine/*deficiency | 3 | 50.0 |
Statistics, Nonparametric | 9 | 0.0 |
Thyroxine/blood | 46 | 17.0 |
Triiodothyronine/blood | 45 | 21.0 |
Gene Expression Regulation/drug effects | 3 | 0.0 |
Kidney/metabolism | 4 | 1.0 |
Lung/metabolism | 2 | 1.0 |
Apolipoprotein A-I/blood | 17 | 15.0 |
Apolipoproteins/*blood | 24 | 15.0 |
Greece | 3 | 3.0 |
Postmenopause/*blood | 3 | 6.0 |
Alanine Transaminase/blood | 7 | 3.0 |
Aspartate Aminotransferases/blood | 4 | 3.0 |
Liver/pathology | 3 | 1.0 |
*Medicine, Chinese Traditional | 2 | 8.0 |
Lipoproteins, VLDL/metabolism | 6 | 5.0 |
Neoplasm, Residual | 8 | 9.0 |
Recombinant Proteins/*diagnostic use | 2 | 66.0 |
Fluorodeoxyglucose F18/*diagnostic use | 4 | 30.0 |
Radiopharmaceuticals/*diagnostic use | 8 | 16.0 |
*Tomography, Emission-Computed | 4 | 9.0 |
*Thiazolidinediones | 5 | 5.0 |
Adenocarcinoma, Follicular/therapy | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Dinucleotide Repeats/genetics | 2 | 4.0 |
Hypertension/*genetics | 2 | 1.0 |
Polymorphism, Single Nucleotide | 2 | 0.0 |
Adenylate Cyclase/metabolism | 3 | 2.0 |
Blotting, Southern | 9 | 0.0 |
Gene Expression/physiology | 5 | 1.0 |
Na(+)-K(+)-Exchanging ATPase/metabolism | 2 | 4.0 |
Transgenes/genetics | 2 | 2.0 |
Cell Line, Tumor | 2 | 0.0 |
DNA Primers | 9 | 0.0 |
Fatty Acids, Nonesterified/blood | 39 | 20.0 |
Insulin/*pharmacology | 3 | 1.0 |
Mice, Knockout | 13 | 0.0 |
Anticholesteremic Agents/therapeutic use | 2 | 6.0 |
Hyperlipidemia/blood/*drug therapy | 10 | 43.0 |
Apolipoproteins E/genetics/*metabolism | 2 | 4.0 |
Binding Sites/drug effects | 2 | 3.0 |
Brain/metabolism/pathology | 7 | 6.0 |
Half-Life | 7 | 1.0 |
Neuroblastoma/metabolism/pathology | 2 | 13.0 |
Infant | 34 | 0.0 |
Infant, Newborn | 36 | 0.0 |
Child, Preschool | 50 | 0.0 |
Hyperlipoproteinemia Type III/*blood | 2 | 33.0 |
Ultracentrifugation/methods | 3 | 15.0 |
Dose-Response Relationship, Drug | 39 | 0.0 |
Glucose/metabolism | 10 | 4.0 |
Lipids/*biosynthesis | 4 | 26.0 |
Stereoisomerism | 3 | 0.0 |
Thiazoles/pharmacology | 4 | 3.0 |
Virulence/genetics | 2 | 2.0 |
DNA/metabolism | 2 | 0.0 |
Hela Cells | 4 | 0.0 |
Polymers | 2 | 1.0 |
Antineoplastic Agents/pharmacology | 4 | 0.0 |
Apoptosis/drug effects/physiology | 2 | 2.0 |
Coculture Techniques | 2 | 0.0 |
Carbon Radioisotopes | 3 | 3.0 |
Cholesterol/analysis/biosynthesis | 2 | 100.0 |
Glycerol/metabolism | 3 | 7.0 |
Isomerism | 4 | 1.0 |
Oleic Acid/pharmacology | 4 | 12.0 |
Tritium | 2 | 0.0 |
Cardiovascular Diseases/*prevention & control | 2 | 12.0 |
Diet | 19 | 5.0 |
Hypothyroidism/blood/congenital/*genetics | 2 | 100.0 |
Pedigree | 18 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Receptors, Thyrotropin/genetics | 5 | 20.0 |
Transcription Factors/genetics | 5 | 0.0 |
Transfection | 13 | 0.0 |
Age Factors | 42 | 1.0 |
Denmark/epidemiology | 2 | 3.0 |
Urban Population | 4 | 3.0 |
Blood Flow Velocity | 2 | 2.0 |
Dietary Fats/administration & dosage | 11 | 12.0 |
Endothelium, Vascular/*physiopathology | 3 | 3.0 |
Hypertriglyceridemia/complications/drug therapy/*physiopathology | 2 | 100.0 |
Oxidative Stress | 8 | 2.0 |
Vasodilation | 2 | 5.0 |
Bone Density | 3 | 2.0 |
Tissue Distribution | 14 | 0.0 |
Arteriosclerosis/etiology | 7 | 10.0 |
Hyperlipidemia/blood/*complications | 2 | 100.0 |
Insulin Resistance/physiology | 4 | 8.0 |
Lipoproteins/blood/drug effects | 3 | 21.0 |
Single-Blind Method | 4 | 1.0 |
United States/epidemiology | 3 | 0.0 |
Crosses, Genetic | 6 | 0.0 |
Protein Isoforms/biosynthesis/genetics | 2 | 3.0 |
Spinal Cord/metabolism/pathology | 5 | 23.0 |
Survival Rate | 7 | 0.0 |
Weight Loss/genetics | 2 | 50.0 |
DNA, Complementary/genetics | 6 | 0.0 |
Exons/genetics | 2 | 0.0 |
Genome | 2 | 0.0 |
Hypothyroidism/*genetics | 3 | 27.0 |
Introns/genetics | 2 | 0.0 |
Thyroglobulin/*genetics | 25 | 75.0 |
Menopause/blood | 3 | 16.0 |
Tamoxifen/adverse effects/*therapeutic use | 2 | 33.0 |
Conserved Sequence | 3 | 0.0 |
Epitopes | 7 | 0.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Thyroglobulin/biosynthesis/*genetics | 6 | 75.0 |
Thyroid Gland/metabolism | 6 | 11.0 |
Aorta/pathology | 2 | 5.0 |
Apolipoproteins A/blood/*genetics | 2 | 16.0 |
Apolipoproteins C/blood/*genetics | 4 | 50.0 |
Arteriosclerosis/*physiopathology | 2 | 11.0 |
*Gene Expression | 9 | 0.0 |
*Membrane Proteins | 10 | 0.0 |
*Receptors, Lipoprotein | 4 | 3.0 |
Transgenes | 6 | 1.0 |
Diagnosis, Differential | 15 | 0.0 |
Alzheimer Disease/pathology | 2 | 9.0 |
Haplotypes | 8 | 0.0 |
Italy | 9 | 1.0 |
Sicily | 2 | 10.0 |
Turkey | 2 | 1.0 |
RNA, Messenger/analysis/metabolism | 2 | 1.0 |
Hypertriglyceridemia/blood/*complications | 4 | 57.0 |
*Peritoneal Dialysis, Continuous Ambulatory | 6 | 5.0 |
Homozygote | 9 | 0.0 |
Lipoprotein Lipase/chemistry/*genetics | 2 | 33.0 |
Longitudinal Studies | 10 | 1.0 |
Heptanoic Acids/therapeutic use | 2 | 33.0 |
Pyrroles/therapeutic use | 2 | 10.0 |
*Body Composition | 10 | 9.0 |
*Diet | 11 | 5.0 |
Fatty Acids, Nonesterified/*metabolism | 2 | 7.0 |
Muscles/metabolism | 2 | 2.0 |
Obesity/complications | 5 | 10.0 |
Weight Loss | 2 | 1.0 |
Coronary Disease/blood | 4 | 14.0 |
Hyperlipidemia/*blood | 11 | 28.0 |
Physical Endurance | 4 | 13.0 |
Alcohol Drinking | 3 | 2.0 |
Coronary Disease/*etiology | 6 | 21.0 |
Diabetes Mellitus, Type 2/blood/*complications | 2 | 10.0 |
Hypertension/complications | 2 | 3.0 |
Smoking/adverse effects | 2 | 0.0 |
*Food | 6 | 6.0 |
Gemfibrozil | 2 | 66.0 |
Hyperlipidemia/blood/drug therapy | 2 | 25.0 |
Lipoproteins, VLDL/blood | 37 | 16.0 |
Nitroprusside/pharmacology | 3 | 4.0 |
Hypercholesterolemia/blood/*drug therapy | 6 | 24.0 |
Biological Availability | 2 | 0.0 |
Blood Glucose/analysis/metabolism | 2 | 22.0 |
Dietary Fats/*administration & dosage/metabolism | 2 | 22.0 |
Blood Pressure/drug effects | 5 | 0.0 |
Hypertension/blood/*drug therapy | 2 | 9.0 |
*Cholesterol | 3 | 33.0 |
Immunosorbent Techniques | 2 | 0.0 |
Cattle | 26 | 0.0 |
Guinea Pigs | 6 | 0.0 |
Protein Conformation | 9 | 0.0 |
Transglutaminases/*metabolism | 8 | 25.0 |
Ca(2+)-Transporting ATPase/metabolism | 2 | 6.0 |
Calcium Channels/metabolism | 2 | 6.0 |
Carbachol/pharmacology | 2 | 2.0 |
Electric Conductivity | 3 | 1.0 |
Patch-Clamp Techniques | 5 | 1.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 2 | 1.0 |
Brain/*metabolism/pathology | 2 | 2.0 |
*Mice, Transgenic | 6 | 14.0 |
Protein Isoforms/genetics/metabolism | 3 | 1.0 |
Spinal Cord/*metabolism/pathology | 2 | 16.0 |
tau Proteins/genetics/*metabolism | 2 | 33.0 |
Fluorodeoxyglucose F18/*diagnostic use/pharmacokinetics | 2 | 66.0 |
Neoplasm Staging | 15 | 0.0 |
Apolipoprotein A-I/*blood | 7 | 21.0 |
Random Allocation | 3 | 0.0 |
Antilipemic Agents/*pharmacology | 6 | 16.0 |
Gemfibrozil/*pharmacology | 5 | 45.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology | 2 | 3.0 |
Liver/*metabolism | 7 | 1.0 |
Fruit | 2 | 7.0 |
*Genes, ras | 5 | 2.0 |
Mice, Inbred Strains | 9 | 1.0 |
Fluorodeoxyglucose F18/diagnostic use | 5 | 26.0 |
Radiopharmaceuticals/diagnostic use | 6 | 10.0 |
Technetium Tc 99m Sestamibi/diagnostic use | 4 | 26.0 |
Tomography, Emission-Computed | 7 | 6.0 |
Carbon Dioxide/metabolism | 2 | 6.0 |
Triglycerides/chemistry | 2 | 25.0 |
Hyperlipidemia/blood/complications/*drug therapy | 2 | 25.0 |
Thromboxane B2/blood | 2 | 5.0 |
Calcium Channel Blockers/pharmacology | 2 | 2.0 |
*Potassium Channels, Voltage-Gated | 2 | 0.0 |
Sulfonamides/pharmacology | 2 | 1.0 |
Fats/metabolism | 2 | 28.0 |
Fatty Acids, Unsaturated/*pharmacology | 3 | 9.0 |
Insulin/metabolism | 6 | 4.0 |
Adipose Tissue/drug effects/*metabolism | 2 | 12.0 |
Blood Glucose/drug effects/metabolism | 2 | 8.0 |
Glucose Clamp Technique | 6 | 5.0 |
Infusions, Intravenous | 6 | 0.0 |
Lipid Mobilization/*drug effects | 3 | 100.0 |
Liver/drug effects/*metabolism | 3 | 4.0 |
Metabolic Clearance Rate | 11 | 3.0 |
Muscle, Skeletal/drug effects/metabolism | 2 | 18.0 |
Obesity/genetics/*physiopathology | 2 | 28.0 |
Rats, Zucker | 7 | 29.0 |
Adenoviridae/genetics | 3 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Nuclear Proteins/*genetics | 3 | 0.0 |
Transduction, Genetic | 2 | 0.0 |
Fatty Acids, Nonesterified/*blood | 13 | 26.0 |
Hypoglycemic Agents/pharmacology | 2 | 6.0 |
Lipolysis/drug effects | 5 | 16.0 |
Patient Selection | 2 | 1.0 |
Infant, Newborn/*blood | 5 | 10.0 |
Nutritional Status | 2 | 1.0 |
Pregnancy/*blood | 4 | 2.0 |
Thyroid Gland/*physiology | 6 | 37.0 |
Turkey/epidemiology | 2 | 2.0 |
Autoantibodies/*immunology | 21 | 8.0 |
Seroepidemiologic Studies | 2 | 1.0 |
Thyroglobulin/*immunology | 77 | 83.0 |
Blood Pressure | 17 | 2.0 |
Prevalence | 21 | 1.0 |
Radioimmunoassay | 57 | 3.0 |
Thyrotropin/*blood | 15 | 12.0 |
Thyroxine/*blood | 7 | 19.0 |
Triiodothyronine/*blood | 7 | 25.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Leukemia, Lymphocytic, Acute/drug therapy/*metabolism | 2 | 40.0 |
Adipocytes/physiology | 3 | 27.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
Insulin-Like Growth Factor I/analysis | 2 | 1.0 |
Catalysis | 2 | 0.0 |
Enzyme Activation | 8 | 0.0 |
Hydrogen-Ion Concentration | 6 | 0.0 |
Trypsin/*metabolism | 3 | 14.0 |
Oxidative Stress/*physiology | 2 | 2.0 |
Superoxide Dismutase/genetics/metabolism | 2 | 5.0 |
Platelet Aggregation | 4 | 2.0 |
Iodine Radioisotopes | 8 | 2.0 |
Recombinant Proteins | 9 | 1.0 |
Thyroid Hormones/*blood | 7 | 11.0 |
Colloids | 3 | 12.0 |
Goiter/metabolism | 3 | 30.0 |
Macromolecular Substances | 2 | 0.0 |
Protein Denaturation | 2 | 0.0 |
Immunoblotting | 6 | 0.0 |
India/ethnology | 2 | 2.0 |
Protein Isoforms/chemistry | 2 | 12.0 |
Statistics | 8 | 1.0 |
Mutation/genetics | 3 | 0.0 |
Animals, Newborn | 7 | 1.0 |
Antibodies | 3 | 0.0 |
Disease Susceptibility | 5 | 0.0 |
Immunization | 11 | 2.0 |
Mice, Inbred BALB C | 14 | 0.0 |
*RNA-Binding Proteins | 2 | 0.0 |
Restriction Mapping | 4 | 0.0 |
Endocytosis | 4 | 1.0 |
Heymann Nephritis Antigenic Complex | 2 | 9.0 |
*Energy Metabolism | 2 | 2.0 |
Exercise Test | 7 | 2.0 |
Physical Fitness | 2 | 8.0 |
Disease-Free Survival | 2 | 0.0 |
Odds Ratio | 6 | 0.0 |
Immunophenotyping | 3 | 0.0 |
L Cells (Cell Line) | 2 | 0.0 |
Mice, Inbred CBA | 12 | 3.0 |
Autoimmunity | 3 | 2.0 |
Thyroid Gland/*immunology | 13 | 21.0 |
Emulsions | 3 | 4.0 |
Lipids/*blood/metabolism | 4 | 33.0 |
Keratin/analysis | 2 | 0.0 |
RNA, Messenger/blood | 2 | 3.0 |
Receptors, Thyrotropin/*blood/genetics | 2 | 100.0 |
Thyroid Neoplasms/*blood/*diagnosis | 2 | 100.0 |
Tumor Markers, Biological/blood | 8 | 5.0 |
Thyroid Neoplasms/blood/*diagnosis | 4 | 100.0 |
Lipoproteins, HDL/*blood/classification | 3 | 27.0 |
Chylomicrons/blood | 12 | 31.0 |
Diabetes Mellitus, Type 2/blood/*drug therapy | 3 | 6.0 |
Fatty Acids/blood | 5 | 11.0 |
Lipoproteins, VLDL Cholesterol/blood | 13 | 20.0 |
Thyroxine/administration & dosage/*therapeutic use | 2 | 50.0 |
Tomography, X-Ray Computed | 11 | 1.0 |
Kidney Failure, Chronic/blood/therapy | 3 | 9.0 |
Kidney, Artificial | 2 | 28.0 |
Renal Dialysis/*adverse effects | 4 | 2.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 4 | 9.0 |
*Aging | 5 | 3.0 |
Microscopy, Electron | 22 | 1.0 |
Artifacts | 2 | 3.0 |
Cyclosporine/therapeutic use | 2 | 2.0 |
Immunosuppressive Agents/therapeutic use | 2 | 0.0 |
Kidney Transplantation | 2 | 1.0 |
Platelet Activation/*physiology | 2 | 3.0 |
beta-Thromboglobulin/analysis | 3 | 3.0 |
Heparin | 3 | 4.0 |
Hydrolysis | 9 | 1.0 |
Lipoproteins, VLDL/*metabolism | 4 | 5.0 |
Recurrence | 20 | 1.0 |
Carrier Proteins/blood/*metabolism | 2 | 9.0 |
Lipoproteins, HDL Cholesterol/blood/*metabolism | 2 | 25.0 |
Lipoproteins, LDL Cholesterol/blood/*metabolism | 3 | 60.0 |
Lipoproteins, VLDL Cholesterol/blood/*metabolism | 2 | 100.0 |
*Phospholipid Transfer Proteins | 4 | 2.0 |
Phospholipids/blood/metabolism | 3 | 75.0 |
Brain/pathology | 4 | 1.0 |
Molecular Weight | 17 | 0.0 |
Trypsin | 3 | 1.0 |
Neoplasm Recurrence, Local | 11 | 2.0 |
Cardiovascular Diseases/blood/*etiology/pathology | 2 | 100.0 |
Electrocardiography | 5 | 1.0 |
Hematocrit | 4 | 1.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Models, Animal | 5 | 2.0 |
Iodide Peroxidase/blood/*immunology | 2 | 40.0 |
Thyroglobulin/blood/immunology | 6 | 85.0 |
Thyroid Diseases/blood/*diagnosis | 2 | 50.0 |
Fatty Acids/metabolism | 10 | 8.0 |
Muscle, Skeletal/*metabolism | 10 | 5.0 |
Obesity/genetics/metabolism | 2 | 14.0 |
Creatine Kinase/metabolism | 2 | 5.0 |
Energy Metabolism | 8 | 4.0 |
*Muscle Proteins | 3 | 1.0 |
Myosin Heavy Chains/genetics | 2 | 9.0 |
Transcription, Genetic | 10 | 0.0 |
Clinical Trials, Phase III | 2 | 4.0 |
Postmenopause/blood | 3 | 10.0 |
Body Composition/physiology | 7 | 12.0 |
Lipoprotein Lipase/blood | 17 | 21.0 |
Calcimycin/pharmacology | 4 | 1.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Ionophores/pharmacology | 3 | 2.0 |
Transgenes/*immunology | 2 | 20.0 |
Chemistry, Clinical/*methods | 2 | 33.0 |
Ultracentrifugation | 12 | 6.0 |
Cardiovascular Diseases/genetics | 2 | 7.0 |
Multigene Family | 3 | 0.0 |
Capillaries | 2 | 3.0 |
Coronary Disease/blood/etiology | 2 | 40.0 |
Eating | 6 | 4.0 |
Biopsy, Needle | 10 | 2.0 |
Neoplasm Recurrence, Local/*diagnosis | 7 | 58.0 |
Chemiluminescent Measurements | 2 | 1.0 |
Immunoassay/methods | 2 | 3.0 |
Thyroid Neoplasms/*blood/therapy | 6 | 100.0 |
Goiter/genetics | 2 | 33.0 |
Iodine/urine | 4 | 80.0 |
Perchloric Acid/diagnostic use | 2 | 66.0 |
Thyroid Gland/pathology | 6 | 19.0 |
Denmark | 3 | 1.0 |
Graves' Disease/*blood/drug therapy | 3 | 50.0 |
Receptors, Thyrotropin/*immunology | 2 | 5.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
*Diet, Vegetarian | 3 | 23.0 |
Erythrocytes/*metabolism | 2 | 0.0 |
Diabetes Mellitus, Type 2/*blood/drug therapy | 2 | 11.0 |
Insulin/therapeutic use | 5 | 4.0 |
Lipoprotein(a)/*blood | 10 | 11.0 |
Sulfonylurea Compounds/therapeutic use | 2 | 16.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Cyclic AMP/metabolism | 3 | 0.0 |
Ligands | 5 | 0.0 |
Thyroglobulin/*genetics/secretion | 3 | 100.0 |
Thyrotropin/pharmacology | 10 | 16.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Deoxyribonuclease HindIII | 2 | 4.0 |
European Continental Ancestry Group | 2 | 0.0 |
Genetic Screening | 2 | 0.0 |
Hispanic Americans | 3 | 4.0 |
Linkage Disequilibrium | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 16 | 0.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Gene Expression/drug effects | 3 | 0.0 |
Nerve Degeneration | 2 | 3.0 |
Lactic Acid/blood | 4 | 9.0 |
Oxygen Consumption | 9 | 3.0 |
Running | 2 | 5.0 |
Nuclear Proteins/*genetics/metabolism | 2 | 1.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Transcription Factors/*genetics/metabolism | 2 | 0.0 |
Amyloid beta-Protein Precursor/metabolism | 2 | 5.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Receptors, LDL/metabolism | 4 | 4.0 |
Iodine Radioisotopes/diagnostic use/therapeutic use | 7 | 70.0 |
Recombinant Proteins/therapeutic use | 6 | 1.0 |
Thyrotropin/*therapeutic use | 4 | 100.0 |
Antioxidants/pharmacology | 4 | 2.0 |
Calcium/metabolism | 6 | 0.0 |
Marine Toxins/pharmacology | 3 | 60.0 |
Mitochondria/drug effects/*metabolism | 2 | 12.0 |
Oxidative Stress/drug effects | 2 | 4.0 |
*Oxocins | 3 | 75.0 |
Transglutaminases/genetics/*metabolism | 3 | 75.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Organ Specificity | 12 | 0.0 |
Radioligand Assay | 4 | 0.0 |
Graves' Disease/metabolism | 5 | 25.0 |
Rats, Inbred Lew | 3 | 1.0 |
Thyroid Diseases/metabolism | 2 | 66.0 |
Thyroid Gland/cytology/*metabolism | 3 | 16.0 |
Thyroglobulin/*biosynthesis | 8 | 100.0 |
Thyroid Neoplasms/*metabolism/pathology | 2 | 4.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Gene Expression/*physiology | 3 | 3.0 |
Superoxide Dismutase/*genetics | 4 | 2.0 |
*Variation (Genetics) | 9 | 0.0 |
Amyloid beta-Protein Precursor/genetics | 2 | 4.0 |
Brain/drug effects/metabolism | 2 | 7.0 |
Neurotransmitters/metabolism | 2 | 5.0 |
Hyperlipoproteinemia/*metabolism | 2 | 25.0 |
*Lipid Peroxidation | 3 | 6.0 |
Lipoproteins, LDL/metabolism | 4 | 1.0 |
*Kidney Transplantation | 3 | 0.0 |
*Renal Dialysis | 8 | 1.0 |
Hypertriglyceridemia/genetics | 3 | 20.0 |
Hormone Replacement Therapy | 2 | 5.0 |
Neck | 3 | 4.0 |
Thyroidectomy/methods | 2 | 66.0 |
Tumor Markers, Biological/*blood | 19 | 4.0 |
*Apoptosis | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Aging/*blood | 4 | 5.0 |
Estrogen Replacement Therapy | 3 | 6.0 |
Adipose Tissue/*physiology | 4 | 22.0 |
Feasibility Studies | 5 | 2.0 |
DNA/biosynthesis | 2 | 0.0 |
Blood Coagulation Factors/*metabolism | 2 | 2.0 |
Electrophoresis, Agar Gel | 5 | 0.0 |
Hypercholesterolemia/*blood | 3 | 14.0 |
Rabbits | 25 | 0.0 |
Chylomicrons/*blood | 4 | 13.0 |
Coronary Disease/etiology | 7 | 20.0 |
Antibodies/*analysis | 7 | 6.0 |
Arteriosclerosis/blood | 2 | 8.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Antibody Specificity | 24 | 1.0 |
Graves' Disease/blood/immunology | 2 | 40.0 |
Thyroglobulin/*blood/*immunology | 6 | 100.0 |
Thyroid Gland/chemistry | 3 | 25.0 |
Carcinoma/diagnosis/pathology | 2 | 40.0 |
*Reverse Transcriptase Polymerase Chain Reaction | 2 | 3.0 |
Carrier Proteins/*genetics/metabolism | 3 | 1.0 |
Chromosome Mapping | 5 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Heart Rate | 5 | 2.0 |
Myocardial Contraction | 4 | 8.0 |
Apolipoproteins A/blood | 11 | 16.0 |
Malondialdehyde/blood | 2 | 3.0 |
*Oxidative Stress | 2 | 0.0 |
*Urban Population | 3 | 21.0 |
Mice, SCID | 5 | 0.0 |
Adenocarcinoma, Follicular/radionuclide imaging/secondary | 2 | 100.0 |
Carcinoma, Papillary/radionuclide imaging/secondary | 2 | 100.0 |
Lung Neoplasms/secondary | 8 | 9.0 |
Lymphatic Metastasis/radionuclide imaging | 2 | 33.0 |
Neoplasm Recurrence, Local/radionuclide imaging | 2 | 50.0 |
Radiopharmaceuticals/*diagnostic use/therapeutic use | 2 | 100.0 |
Technetium Tc 99m Sestamibi/*diagnostic use | 4 | 33.0 |
Hyperlipoproteinemia Type IV/blood | 2 | 20.0 |
Culture Media | 2 | 0.0 |
Insulin/*metabolism | 2 | 2.0 |
Autoimmune Diseases/*genetics | 2 | 4.0 |
Chromosomes, Human, Pair 8/genetics | 2 | 2.0 |
Linkage (Genetics) | 4 | 0.0 |
Biopsy | 6 | 0.0 |
Drug Administration Schedule | 8 | 0.0 |
Neck/*ultrasonography | 3 | 60.0 |
Thyroxine/administration & dosage | 3 | 60.0 |
Absorption | 3 | 2.0 |
Margarine | 2 | 50.0 |
Iodine Radioisotopes/*diagnostic use/*therapeutic use | 4 | 80.0 |
Lymph Nodes/radionuclide imaging | 2 | 50.0 |
Lymphatic Metastasis | 22 | 2.0 |
*Blood Pressure | 3 | 2.0 |
Diastole | 2 | 2.0 |
Insulin/*blood/secretion | 2 | 16.0 |
Circadian Rhythm | 4 | 1.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Adipose Tissue/*anatomy & histology | 3 | 5.0 |
Heparin/*pharmacology | 5 | 3.0 |
*Linkage (Genetics) | 2 | 0.0 |
Lipase/*blood | 4 | 6.0 |
Polymorphism, Genetic/genetics | 5 | 0.0 |
Postoperative Care | 4 | 5.0 |
Thallium Radioisotopes/diagnostic use | 3 | 13.0 |
Thyroid Neoplasms/blood/*radionuclide imaging/*radiotherapy | 2 | 100.0 |
Phospholipids/blood | 20 | 15.0 |
Blood Specimen Collection | 2 | 4.0 |
Drug Stability | 3 | 1.0 |
Mass Fragmentography | 4 | 1.0 |
Clofibric Acid/*analogs & derivatives/therapeutic use | 2 | 40.0 |
Lipids/analysis | 3 | 6.0 |
*Obesity | 2 | 3.0 |
Proteins/*metabolism | 3 | 0.0 |
Exertion/*physiology | 3 | 4.0 |
Swimming | 3 | 23.0 |
Adipocytes/drug effects/metabolism | 2 | 16.0 |
CD4 Lymphocyte Count | 3 | 0.0 |
Obesity/chemically induced | 2 | 100.0 |
Antilipemic Agents/*administration & dosage | 2 | 14.0 |
Bezafibrate/*administration & dosage | 2 | 40.0 |
Diabetes Mellitus, Type 2/*blood/*drug therapy | 2 | 18.0 |
*Chromosome Mapping | 4 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Lod Score | 5 | 0.0 |
Neoplasm Metastasis/diagnosis | 4 | 25.0 |
Thyrotropin/diagnostic use | 5 | 83.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
*Alleles | 3 | 0.0 |
Serine/genetics | 2 | 2.0 |
Variation (Genetics)/*genetics | 3 | 1.0 |
Magnetic Resonance Imaging | 6 | 0.0 |
Histocytochemistry | 8 | 1.0 |
Prolactin/blood | 3 | 0.0 |
*Heterozygote | 4 | 1.0 |
Smoking/*adverse effects | 3 | 1.0 |
*Thyroid Gland | 2 | 50.0 |
Apolipoprotein A-I/*blood/genetics | 2 | 50.0 |
Pravastatin/therapeutic use | 2 | 12.0 |
Dietary Carbohydrates/administration & dosage/*pharmacology | 2 | 66.0 |
Carrier Proteins/blood | 4 | 3.0 |
Central Nervous System/pathology | 2 | 9.0 |
*Genes, MHC Class II | 2 | 0.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Myelin Basic Proteins/immunology | 2 | 2.0 |
Peptide Fragments/immunology | 3 | 1.0 |
T-Lymphocytes/immunology | 17 | 1.0 |
Hemagglutination Tests | 6 | 7.0 |
Thyroid Gland/immunology | 10 | 23.0 |
Chemistry, Physical | 3 | 2.0 |
Clinical Trials | 9 | 0.0 |
Hypertriglyceridemia/blood/*metabolism | 2 | 50.0 |
Lipoproteins, VLDL/chemistry/*metabolism | 2 | 20.0 |
Structure-Activity Relationship | 9 | 0.0 |
Temperature | 5 | 0.0 |
Hyperlipidemia/*blood/etiology | 3 | 75.0 |
Apolipoproteins C/*blood | 13 | 41.0 |
Apolipoproteins E/*blood | 9 | 16.0 |
Immunodiffusion | 7 | 2.0 |
Diet, Atherogenic | 2 | 6.0 |
Apolipoprotein A-I/*genetics | 3 | 10.0 |
Asian Continental Ancestry Group | 5 | 1.0 |
Peritoneal Dialysis, Continuous Ambulatory/*adverse effects | 3 | 7.0 |
Thyroid Hormones/blood | 15 | 15.0 |
Thyrotropin/analysis | 2 | 16.0 |
Thyroxine/analysis | 6 | 85.0 |
Triiodothyronine/analysis | 5 | 83.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Caco-2 Cells | 2 | 0.0 |
Enzyme Inhibitors/*therapeutic use | 2 | 2.0 |
Liver/drug effects/metabolism/pathology | 2 | 28.0 |
Triglycerides/*biosynthesis/blood | 3 | 100.0 |
False Negative Reactions | 6 | 4.0 |
Thyroiditis, Autoimmune/*blood/immunology | 2 | 66.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*genetics | 3 | 2.0 |
Mutation/*genetics | 6 | 0.0 |
Mutation, Missense/genetics | 2 | 1.0 |
*Genetic Vectors | 3 | 0.0 |
Smoking | 3 | 0.0 |
Signal Transduction | 6 | 0.0 |
Cardiovascular Diseases/*epidemiology | 2 | 15.0 |
Coronary Disease/epidemiology | 5 | 26.0 |
*Point Mutation | 4 | 0.0 |
Risk | 9 | 1.0 |
Thyroid Gland/*enzymology | 2 | 10.0 |
Hemoglobin A, Glycosylated/metabolism | 4 | 2.0 |
Fasting/*blood | 3 | 18.0 |
Hemostasis/*drug effects | 2 | 3.0 |
Chromatography, Gas | 4 | 4.0 |
Fatty Acids/*blood | 3 | 10.0 |
Neoplasm Recurrence, Local/blood | 3 | 18.0 |
COS Cells | 3 | 0.0 |
Isotope Labeling | 4 | 5.0 |
Aging/*physiology | 6 | 2.0 |
*Immunoconjugates | 2 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 6 | 1.0 |
Syndrome | 7 | 0.0 |
Epidemiologic Methods | 2 | 3.0 |
Thyroid Neoplasms/*diagnosis/radiotherapy/surgery | 3 | 100.0 |
Hypercholesterolemia/*epidemiology | 3 | 75.0 |
Taiwan/epidemiology | 4 | 3.0 |
Recombinant Proteins/administration & dosage | 3 | 3.0 |
Thyroid Neoplasms/*blood/radionuclide imaging/therapy | 2 | 100.0 |
Thyroxine/administration & dosage/therapeutic use | 3 | 100.0 |
Antibodies/blood | 2 | 3.0 |
Radioimmunoassay/*methods | 8 | 11.0 |
Skin | 3 | 4.0 |
Viscera | 5 | 16.0 |
Dietary Carbohydrates/*administration & dosage | 4 | 16.0 |
Bacteriophage lambda/genetics | 2 | 4.0 |
DNA Primers/genetics | 2 | 0.0 |
*Genome, Human | 2 | 0.0 |
*Radioimmunoassay | 2 | 5.0 |
Lipoprotein Lipase/*deficiency/*genetics | 2 | 14.0 |
Adipose Tissue/metabolism | 8 | 6.0 |
Dietary Fats/*metabolism | 7 | 30.0 |
Fatty Acids, Nonesterified/blood/metabolism | 2 | 40.0 |
Liver/metabolism/secretion | 2 | 66.0 |
Antibodies, Monoclonal/immunology | 7 | 0.0 |
Receptors, Virus/genetics/*metabolism | 2 | 6.0 |
Hyperlipidemia/*metabolism | 2 | 13.0 |
Thallium Radioisotopes/*diagnostic use | 3 | 30.0 |
Adipose Tissue/*enzymology | 5 | 9.0 |
Lipoprotein Lipase/genetics/*metabolism | 2 | 6.0 |
Iodide Peroxidase/genetics | 3 | 27.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
*Symporters | 2 | 2.0 |
Thyroglobulin/genetics | 4 | 21.0 |
Thyroid Neoplasms/*metabolism | 5 | 12.0 |
Thyroid Diseases/*diagnosis | 2 | 66.0 |
Asparagine/*genetics | 2 | 22.0 |
*Exons | 2 | 0.0 |
*Frameshift Mutation | 2 | 1.0 |
Iodide Peroxidase/*genetics | 5 | 12.0 |
Blood Pressure/physiology | 4 | 2.0 |
Heart Rate/physiology | 4 | 4.0 |
Hypertension/*blood/physiopathology | 2 | 15.0 |
Coronary Disease/*genetics | 3 | 4.0 |
Gene Deletion | 3 | 0.0 |
Microscopy, Confocal | 4 | 0.0 |
Oxygen/metabolism | 2 | 0.0 |
Protein Isoforms | 3 | 0.0 |
Spinal Cord/pathology | 2 | 2.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
Cardiotonic Agents | 2 | 100.0 |
Dietary Supplements | 2 | 2.0 |
Fish Oils | 4 | 100.0 |
Brain/*metabolism | 5 | 1.0 |
Reactive Oxygen Species/metabolism | 3 | 0.0 |
Superoxide Dismutase/*genetics/metabolism | 4 | 8.0 |
Thyroid Neoplasms/metabolism/*radionuclide imaging | 2 | 100.0 |
Arteriosclerosis/*blood | 3 | 14.0 |
Macrophages/metabolism | 4 | 1.0 |
Thyroid Neoplasms/pathology/*radionuclide imaging/therapy | 2 | 100.0 |
Iodine/metabolism | 9 | 39.0 |
Thyroglobulin/blood/*metabolism | 5 | 100.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Nuclear Proteins/genetics | 2 | 0.0 |
Thyroid Gland | 3 | 37.0 |
Thyroid Neoplasms/*genetics | 3 | 3.0 |
Trans-Activators/genetics | 2 | 0.0 |
*Gene Expression Regulation | 5 | 0.0 |
Age of Onset | 3 | 0.0 |
Carbohydrates/metabolism | 3 | 5.0 |
Insulin Resistance/*genetics | 3 | 3.0 |
*Thyroid Function Tests | 3 | 23.0 |
Triiodothyronine, Reverse/blood | 4 | 14.0 |
Drug Combinations | 2 | 0.0 |
*Genes, bcl-2 | 2 | 3.0 |
Transplantation, Heterologous | 2 | 0.0 |
Adipose Tissue/*metabolism | 10 | 9.0 |
*Dietary Supplements | 2 | 3.0 |
Eating/*physiology | 6 | 8.0 |
Fatty Acids, Omega-3/*therapeutic use | 4 | 40.0 |
Chromatography, Liquid | 3 | 2.0 |
Lipoproteins, LDL/*metabolism | 2 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Amino Acid Chloromethyl Ketones/*pharmacology | 2 | 25.0 |
Cell Survival | 2 | 0.0 |
Clone Cells | 3 | 0.0 |
Cysteine Proteinase Inhibitors/*pharmacology | 2 | 6.0 |
Dogs | 6 | 0.0 |
Triglycerides/*analysis/metabolism | 2 | 100.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Lipoproteins, VLDL/*pharmacology | 2 | 66.0 |
Ultraviolet Rays | 2 | 0.0 |
Thyroid Neoplasms/blood/*radiotherapy/*surgery | 2 | 100.0 |
Dietary Fats/administration & dosage/*metabolism | 3 | 37.0 |
Obesity/*metabolism | 8 | 10.0 |
Antibodies, Monoclonal/diagnostic use | 4 | 0.0 |
Antithyroid Agents/therapeutic use | 3 | 23.0 |
Thyroid Diseases/blood | 3 | 30.0 |
Thyroid Neoplasms/blood | 9 | 69.0 |
Factor VII/*analysis | 2 | 11.0 |
Centrifugation, Density Gradient | 5 | 1.0 |
Lipoproteins, LDL/*blood/chemistry | 6 | 31.0 |
Lipoproteins, HDL/*metabolism | 2 | 1.0 |
Phosphatidylcholines/metabolism | 2 | 2.0 |
Genome, Human | 3 | 0.0 |
Apolipoprotein A-II/blood | 2 | 10.0 |
Thyroglobulin/chemistry/*genetics/metabolism | 2 | 100.0 |
Blood Glucose/*analysis | 4 | 3.0 |
Antioxidants/metabolism | 2 | 2.0 |
Biological Markers/analysis | 3 | 0.0 |
Gene Expression Regulation, Enzymologic/genetics | 2 | 3.0 |
*Biopsy, Needle | 3 | 8.0 |
Thyroid Neoplasms/*chemistry/pathology/surgery | 2 | 100.0 |
Leptin | 2 | 1.0 |
Amyotrophic Lateral Sclerosis/genetics/pathology/physiopathology | 2 | 100.0 |
Mice, Mutant Strains | 4 | 0.0 |
Physical Fitness/physiology | 2 | 16.0 |
Japan/epidemiology | 5 | 1.0 |
Apolipoproteins A/*genetics | 5 | 10.0 |
Densitometry | 4 | 2.0 |
Regional Blood Flow | 2 | 1.0 |
Apolipoproteins E/genetics | 3 | 0.0 |
Cholesterol/analysis | 3 | 6.0 |
Chromatography, Affinity/methods | 2 | 2.0 |
Hypertriglyceridemia/metabolism | 3 | 42.0 |
Cholesterol/*metabolism | 3 | 1.0 |
*Intestinal Absorption | 5 | 14.0 |
*Alcohol Drinking | 3 | 12.0 |
Arteriosclerosis/prevention & control | 3 | 12.0 |
Adenocarcinoma/*blood | 2 | 14.0 |
Carcinoma, Papillary/blood | 2 | 50.0 |
Goiter/blood | 4 | 100.0 |
Thyroid Neoplasms/*blood | 11 | 68.0 |
Thyroid Diseases/genetics | 2 | 66.0 |
Thyroid Gland/*pathology | 4 | 28.0 |
Thyroid Neoplasms/*genetics/pathology | 2 | 6.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Cholesterol Esters/metabolism | 2 | 1.0 |
Oleic Acid/metabolism | 3 | 14.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
Dietary Fats, Unsaturated/*pharmacology | 2 | 50.0 |
Dietary Fats/*pharmacokinetics | 2 | 28.0 |
*HIV-1 | 2 | 0.0 |
Thyroxine-Binding Proteins/analysis | 4 | 28.0 |
Diabetes Mellitus/*blood | 2 | 2.0 |
Plasminogen Activator Inhibitor 1/*blood | 3 | 9.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Spinal Cord/*metabolism | 2 | 6.0 |
Apolipoproteins B/*secretion | 4 | 16.0 |
Glucose/*pharmacology | 3 | 3.0 |
Triglycerides/*biosynthesis | 5 | 50.0 |
Hypercholesterolemia, Familial/*blood | 3 | 17.0 |
Autoantibodies/blood/immunology | 2 | 10.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
T-Lymphocytes, Cytotoxic/immunology | 2 | 0.0 |
Guanine | 3 | 3.0 |
Heterozygote Detection | 2 | 0.0 |
*Sequence Deletion | 2 | 0.0 |
Thymine | 3 | 5.0 |
Gene Expression Regulation, Viral | 2 | 0.0 |
Virulence | 3 | 1.0 |
Virus Replication | 2 | 0.0 |
Antibodies, Monoclonal | 12 | 0.0 |
*Birth Weight | 3 | 7.0 |
Maternal-Fetal Exchange | 5 | 3.0 |
Biological Transport/drug effects | 2 | 0.0 |
*Epitope Mapping | 2 | 3.0 |
Immunodominant Epitopes/*immunology | 2 | 6.0 |
Immunoglobulin G/*analysis | 4 | 5.0 |
Free Radicals | 3 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*physiology | 2 | 8.0 |
Apolipoproteins/*genetics | 3 | 4.0 |
Cardiovascular Diseases/etiology | 3 | 6.0 |
Carrier Proteins/*blood | 3 | 1.0 |
Forearm | 2 | 8.0 |
Glycerol/blood | 9 | 23.0 |
Hydroxybutyrates/blood | 3 | 18.0 |
Lactates/blood | 3 | 4.0 |
Antibodies, Monoclonal/chemistry/*immunology | 2 | 14.0 |
Autoantigens/*immunology | 14 | 8.0 |
Iodine/*immunology | 3 | 100.0 |
Thyroglobulin/analogs & derivatives/*immunology | 2 | 100.0 |
Thyroxine/immunology | 7 | 77.0 |
Triiodothyronine, Reverse/immunology | 2 | 100.0 |
Autoimmune Diseases/immunology | 8 | 9.0 |
Epitope Mapping | 2 | 0.0 |
*Body Mass Index | 5 | 5.0 |
Liver/*enzymology | 8 | 1.0 |
Hydroxymethylglutaryl CoA Reductases/metabolism | 2 | 11.0 |
Cardiovascular Diseases/*etiology | 2 | 6.0 |
Insulin/*blood/immunology | 2 | 100.0 |
Hypercholesterolemia/*drug therapy | 3 | 27.0 |
Placebos | 5 | 2.0 |
False Positive Reactions | 7 | 3.0 |
Neoplasm Metastasis/radionuclide imaging | 2 | 66.0 |
Thyroid Neoplasms/pathology/*radionuclide imaging | 2 | 100.0 |
Species Specificity | 17 | 0.0 |
DNA/analysis/genetics | 3 | 2.0 |
Fatty Acids/*metabolism | 5 | 5.0 |
Lipolysis/physiology | 2 | 22.0 |
Neurons/metabolism | 2 | 0.0 |
Hyperlipidemia/*complications/physiopathology | 2 | 100.0 |
*Dietary Fats | 5 | 23.0 |
Magnetic Resonance Spectroscopy | 3 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Pyrazines/*therapeutic use | 2 | 25.0 |
Tissue Plasminogen Activator/blood | 2 | 1.0 |
Diazomethane/analogs & derivatives/pharmacology | 2 | 100.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Ribavirin/analogs & derivatives/pharmacology | 2 | 100.0 |
Substrate Specificity | 5 | 0.0 |
Kidney Failure, Chronic/*blood | 3 | 4.0 |
Mathematics | 3 | 1.0 |
Nephrotic Syndrome/*blood | 2 | 13.0 |
Antigens, Differentiation/*genetics | 2 | 1.0 |
Immunoglobulins, Heavy-Chain/genetics | 2 | 1.0 |
Dietary Carbohydrates | 2 | 8.0 |
Lipoproteins, VLDL/*biosynthesis | 3 | 50.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
Blood Proteins/metabolism | 2 | 0.0 |
Chromatography, Gel | 14 | 1.0 |
Lipase/metabolism | 3 | 5.0 |
Liver/enzymology | 8 | 1.0 |
Castration | 3 | 6.0 |
Chorionic Gonadotropin/pharmacology | 2 | 1.0 |
DNA Replication/drug effects | 2 | 1.0 |
Glucagon/blood | 8 | 8.0 |
Inflammation | 3 | 0.0 |
Organophosphorus Compounds/*diagnostic use | 2 | 14.0 |
Organotechnetium Compounds/*diagnostic use | 2 | 8.0 |
Brazil | 2 | 0.0 |
Goiter/congenital/*genetics | 3 | 75.0 |
Lipoproteins, VLDL/pharmacology | 2 | 12.0 |
Vitamin A/analogs & derivatives/blood | 3 | 50.0 |
Fetal Blood/*metabolism | 3 | 6.0 |
Thyroid Gland/*physiopathology | 4 | 14.0 |
Superoxide Dismutase/*metabolism | 2 | 5.0 |
Body Composition/*physiology | 2 | 5.0 |
Calcium/*blood | 4 | 4.0 |
Cell Movement/drug effects | 2 | 0.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Neutrophils/*drug effects/metabolism | 2 | 4.0 |
Food | 5 | 4.0 |
Myocardial Infarction/genetics | 3 | 12.0 |
Cell Differentiation/physiology | 3 | 0.0 |
Thyroid Neoplasms/*immunology/pathology | 3 | 42.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Swine | 10 | 0.0 |
Dietary Fats/administration & dosage/*pharmacology | 2 | 15.0 |
*Glucose Tolerance Test | 7 | 12.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Immunologic Techniques | 7 | 2.0 |
Interleukin-1/*pharmacology | 3 | 0.0 |
Permeability | 2 | 1.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Human Growth Hormone/blood | 2 | 3.0 |
Hydrocortisone/blood | 4 | 0.0 |
Fat Emulsions, Intravenous/*pharmacokinetics | 2 | 50.0 |
Thyroxine/*therapeutic use | 6 | 33.0 |
Deoxyribonucleases, Type II Site-Specific | 2 | 0.0 |
India | 2 | 0.0 |
Thyroid Neoplasms/*pathology/radiotherapy/surgery | 2 | 66.0 |
Lipoproteins/*blood/chemistry | 2 | 16.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Immunoglobulin G/biosynthesis | 8 | 5.0 |
Receptors, Thyrotropin/immunology | 3 | 16.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 2 | 1.0 |
Autoantibodies/analysis/*immunology | 3 | 30.0 |
Immunoglobulin G/analysis | 6 | 1.0 |
Immunoglobulin M/analysis | 5 | 2.0 |
Thyroxine/*immunology | 4 | 80.0 |
Triiodothyronine/*immunology | 3 | 60.0 |
CHO Cells/metabolism | 2 | 5.0 |
Cricetulus | 2 | 0.0 |
Genes, Synthetic | 2 | 3.0 |
Glial Fibrillary Acidic Protein/genetics | 2 | 7.0 |
Hamsters | 7 | 0.0 |
Imidazoles/pharmacology | 2 | 0.0 |
Adipose Tissue | 4 | 7.0 |
Aging/*metabolism | 3 | 1.0 |
Estradiol/*blood | 3 | 1.0 |
*Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Acute Disease | 4 | 0.0 |
Injections, Intravenous | 6 | 0.0 |
Portal Vein | 2 | 9.0 |
Liver/*cytology | 2 | 6.0 |
Peptide Hydrolases/*metabolism | 2 | 2.0 |
Receptors, Immunologic/*genetics | 2 | 1.0 |
*Twins | 2 | 7.0 |
Epitopes/analysis | 2 | 0.0 |
Mice, Inbred A | 2 | 3.0 |
Thyronines/*immunology | 2 | 100.0 |
Diabetes Mellitus, Type 1/*immunology | 2 | 2.0 |
Thapsigargin/*pharmacology | 2 | 40.0 |
Medical Records | 2 | 2.0 |
Animal Feed | 2 | 11.0 |
Mice, Transgenic/*genetics | 6 | 18.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Frameshift Mutation | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Infant, Premature/*blood | 3 | 9.0 |
Insulin-Like Growth Factor I/metabolism | 2 | 1.0 |
Protirelin/diagnostic use | 5 | 3.0 |
Carcinoma, Papillary/*blood/radionuclide imaging/therapy | 2 | 100.0 |
Graves' Disease/*genetics | 2 | 5.0 |
Receptors, Thyrotropin/*genetics | 2 | 3.0 |
Hyperlipidemia/*genetics | 2 | 9.0 |
Thyroid Neoplasms/blood/*surgery | 2 | 100.0 |
*Asian Continental Ancestry Group | 2 | 3.0 |
Diabetes Complications | 3 | 2.0 |
Fibrinogen/*metabolism | 3 | 4.0 |
Thyroid Gland/physiology | 3 | 23.0 |
Antibodies, Monoclonal/*diagnostic use | 3 | 1.0 |
Thyroglobulin/*immunology/metabolism | 7 | 87.0 |
Lipids/*blood/genetics | 2 | 25.0 |
Lipoproteins/*blood/genetics | 3 | 33.0 |
*Epitopes | 4 | 2.0 |
Hyperplasia | 2 | 0.0 |
Oncogenes | 2 | 0.0 |
*Repressor Proteins | 2 | 0.0 |
Anticholesteremic Agents/adverse effects/*therapeutic use | 3 | 42.0 |
Homeostasis | 2 | 0.0 |
Receptors, Virus/genetics | 2 | 20.0 |
*Postmenopause | 2 | 3.0 |
Muscle, Skeletal/metabolism | 3 | 1.0 |
Triglycerides/*blood/*metabolism | 2 | 66.0 |
Obesity/physiopathology | 3 | 11.0 |
Physical Endurance/physiology | 3 | 9.0 |
Chromatography | 2 | 1.0 |
Cyclic AMP/biosynthesis | 2 | 1.0 |
Receptors, Thyrotropin/metabolism | 2 | 50.0 |
Thyrotropin/metabolism | 3 | 5.0 |
Epitopes, T-Lymphocyte/*immunology | 3 | 5.0 |
Peptide Fragments/*immunology | 2 | 1.0 |
Rats, Inbred Strains/*immunology | 2 | 33.0 |
Simvastatin | 7 | 24.0 |
Carcinoma/diagnosis | 2 | 40.0 |
Goiter/diagnosis | 2 | 100.0 |
Lovastatin/analogs & derivatives/therapeutic use | 2 | 66.0 |
Procetofen/therapeutic use | 2 | 40.0 |
Kidney/pathology | 2 | 1.0 |
Oxygen Consumption/physiology | 2 | 2.0 |
Poland | 3 | 2.0 |
Neoplasm Metastasis/*radionuclide imaging | 2 | 66.0 |
Cell Membrane/drug effects | 2 | 5.0 |
Amino Acids/metabolism | 2 | 2.0 |
Bezafibrate/*therapeutic use | 3 | 21.0 |
Drug Tolerance | 2 | 1.0 |
Dietary Fats/*pharmacology | 8 | 12.0 |
Hypertension/etiology | 2 | 4.0 |
Thyroid Gland/physiopathology | 2 | 10.0 |
Estrogens/*pharmacology | 2 | 2.0 |
Activins | 2 | 2.0 |
Cell Division/drug effects | 6 | 0.0 |
Estradiol/blood | 2 | 0.0 |
Homeostasis/*genetics | 2 | 15.0 |
Progesterone/blood | 2 | 0.0 |
Ganciclovir/pharmacology | 2 | 6.0 |
Thyroid Diseases/*pathology | 2 | 50.0 |
Fish Oils/*therapeutic use | 3 | 42.0 |
Hypoglycemic Agents/therapeutic use | 2 | 4.0 |
Insulin/pharmacology | 4 | 1.0 |
Brain Injuries/*metabolism | 2 | 18.0 |
DNA Fragmentation | 2 | 0.0 |
Protons | 2 | 2.0 |
Freeze Drying | 2 | 8.0 |
Iodide Peroxidase/*metabolism | 2 | 8.0 |
*Iodine Radioisotopes | 3 | 37.0 |
Isotope Labeling/methods | 3 | 13.0 |
Peptide Fragments/chemistry/isolation & purification | 2 | 5.0 |
Peptide Mapping | 2 | 0.0 |
Antibodies, Monoclonal/*immunology | 10 | 1.0 |
Immune Sera/immunology | 3 | 1.0 |
Immunoglobulin Idiotypes/*analysis | 2 | 28.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Antilipemic Agents/pharmacology | 2 | 14.0 |
Amyloid beta-Protein Precursor/genetics/*metabolism | 2 | 7.0 |
Endothelium/enzymology | 2 | 10.0 |
Fibrin/*metabolism | 2 | 5.0 |
Socioeconomic Factors | 2 | 1.0 |
Albuminuria | 2 | 4.0 |
Family | 3 | 0.0 |
Palmitic Acid | 2 | 12.0 |
Hyperlipidemia/physiopathology | 3 | 75.0 |
Binding, Competitive | 18 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Myocardium/*metabolism/pathology | 2 | 7.0 |
Insulin/*secretion | 3 | 3.0 |
Hyperlipidemia/*blood/complications | 3 | 75.0 |
Anaerobic Threshold/physiology | 3 | 27.0 |
Fatty Acids, Omega-3/*pharmacology | 3 | 27.0 |
Pulmonary Gas Exchange/physiology | 2 | 14.0 |
Hypertriglyceridemia/blood/complications/*drug therapy | 2 | 50.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Antigens | 3 | 3.0 |
CD4-Positive T-Lymphocytes/*immunology | 2 | 0.0 |
Lymph Nodes/immunology | 2 | 2.0 |
T-Lymphocytes/*immunology | 13 | 0.0 |
Autoantigens/immunology | 4 | 2.0 |
*Immune Tolerance | 3 | 1.0 |
Spleen/immunology | 4 | 2.0 |
Heparin/diagnostic use | 3 | 33.0 |
Lipase/blood | 5 | 6.0 |
*Genes | 2 | 0.0 |
Lipoproteins/*metabolism | 5 | 3.0 |
Oleic Acid | 7 | 11.0 |
Oleic Acids/metabolism | 3 | 14.0 |
Fish Oils/*administration & dosage | 2 | 20.0 |
Vitamin E/blood | 2 | 4.0 |
Stimulation, Chemical | 4 | 0.0 |
Blood Glucose/*metabolism | 16 | 6.0 |
Hydrocortisone/*blood | 2 | 1.0 |
Lipoproteins, LDL/*blood/isolation & purification | 3 | 25.0 |
Thyroxine-Binding Proteins/metabolism | 2 | 14.0 |
Triiodothyronine/therapeutic use | 2 | 33.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Thyroglobulin/genetics/*metabolism | 2 | 100.0 |
Thyrotropin/*physiology | 2 | 18.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Molecular Probes/genetics | 3 | 3.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Arachidonic Acid/metabolism | 2 | 2.0 |
Pre-Eclampsia/*blood | 4 | 8.0 |
Pregnancy Complications, Hematologic/*blood | 2 | 12.0 |
Terpenes/*pharmacology | 5 | 26.0 |
Thapsigargin | 9 | 32.0 |
*Body Constitution | 2 | 7.0 |
Nerve Growth Factors/*pharmacology | 2 | 1.0 |
Diabetes Mellitus, Type 2/complications | 2 | 9.0 |
Hyperlipidemia/complications | 4 | 28.0 |
Cyclic AMP/*biosynthesis | 5 | 17.0 |
*Mass Screening | 2 | 3.0 |
Skin/*pathology | 2 | 2.0 |
Iodine/*therapeutic use | 3 | 75.0 |
Thyroid Gland/metabolism/pathology | 4 | 33.0 |
Immunoradiometric Assay/*methods | 2 | 28.0 |
Alcohol Drinking/epidemiology | 3 | 15.0 |
Mass Screening | 3 | 1.0 |
Image Processing, Computer-Assisted | 3 | 0.0 |
Chylomicrons/*metabolism | 5 | 15.0 |
Amino Acids/analysis | 2 | 0.0 |
Immunoassay/*instrumentation | 2 | 50.0 |
Iodine/analysis | 3 | 60.0 |
Reference Standards | 4 | 1.0 |
Hydrochlorothiazide/administration & dosage/pharmacology/therapeutic use | 2 | 100.0 |
Lipoproteins, HDL/*blood/drug effects | 2 | 100.0 |
Apoptosis/drug effects | 2 | 0.0 |
Finland | 5 | 1.0 |
Nitric-Oxide Synthase/*genetics/metabolism | 2 | 10.0 |
Serum Albumin/analysis | 5 | 2.0 |
Triglycerides/blood/chemistry | 2 | 28.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Autoantibodies/immunology | 8 | 7.0 |
Monosaccharide Transport Proteins/*metabolism | 2 | 7.0 |
Subcellular Fractions/metabolism | 2 | 0.0 |
Triglycerides/*blood/metabolism | 4 | 36.0 |
Chromatography, Affinity | 10 | 1.0 |
Thyroglobulin/chemistry/*metabolism | 2 | 100.0 |
Epithelial Cells | 3 | 0.0 |
Plasmids/genetics | 3 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
Lipids/*analysis | 2 | 15.0 |
Hypertension/*blood | 2 | 3.0 |
Rats, Wistar | 4 | 0.0 |
Apolipoprotein A-I/metabolism | 6 | 8.0 |
Lipolysis/*drug effects | 2 | 6.0 |
Adipose Tissue/*pathology | 2 | 11.0 |
Indium Radioisotopes/*diagnostic use | 2 | 11.0 |
Octreotide/*diagnostic use | 2 | 66.0 |
Receptors, Somatostatin/metabolism | 2 | 11.0 |
Mesocricetus | 2 | 1.0 |
Receptor, Insulin/physiology | 2 | 16.0 |
Glucose/pharmacology | 2 | 1.0 |
Genome, Viral | 2 | 1.0 |
Transplantation, Homologous | 2 | 0.0 |
Thyroid Diseases/*blood/immunology | 2 | 100.0 |
Poliovirus Vaccine, Oral | 2 | 66.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 3 | 8.0 |
Muscles/*metabolism | 3 | 4.0 |
*Exertion | 10 | 6.0 |
Lactoperoxidase/metabolism | 2 | 28.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Thyroglobulin/*pharmacology | 3 | 60.0 |
Graves' Disease/*immunology | 11 | 12.0 |
Toxoplasma/*immunology | 2 | 9.0 |
Creatinine/blood | 4 | 1.0 |
Heart Rate/drug effects | 2 | 0.0 |
Uric Acid/blood | 3 | 5.0 |
RNA, Messenger | 3 | 0.0 |
Thyroiditis, Autoimmune/immunology | 9 | 26.0 |
*Polymorphism, Single Nucleotide | 4 | 0.0 |
Interleukin-2/genetics | 2 | 2.0 |
Histamine/pharmacology | 2 | 3.0 |
Terpenes/pharmacology | 3 | 11.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Tumor Necrosis Factor-alpha/*analysis | 2 | 0.0 |
Diabetes Mellitus, Type 2/*blood/*complications | 2 | 40.0 |
Electrophoresis, Polyacrylamide Gel/methods | 2 | 1.0 |
Diet, Reducing | 3 | 9.0 |
Immunoglobulin G/classification/immunology | 2 | 28.0 |
Goiter/*genetics/metabolism | 3 | 100.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
Graves' Disease/blood | 4 | 40.0 |
Thyroiditis, Autoimmune/blood | 2 | 50.0 |
Lipoprotein Lipase/metabolism | 6 | 5.0 |
CHO Cells | 2 | 0.0 |
Phosphatidylcholines/*metabolism | 2 | 4.0 |
Lipase/*metabolism | 4 | 7.0 |
Blood Platelets/*drug effects/metabolism | 2 | 5.0 |
Endothelins/*pharmacology | 2 | 33.0 |
Ca(2+)-Transporting ATPase/*antagonists & inhibitors | 2 | 28.0 |
Iodine/*deficiency/urine | 2 | 66.0 |
Potassium Iodide/therapeutic use | 2 | 100.0 |
Brain Chemistry | 2 | 0.0 |
Diabetes Mellitus, Type 2/*genetics | 2 | 1.0 |
Thyroxine/blood/*therapeutic use | 4 | 40.0 |
Blood Platelets/metabolism | 3 | 1.0 |
*Platelet Activation | 2 | 1.0 |
Cholesterol Esters/*analysis | 2 | 100.0 |
Fatty Acids/*analysis | 2 | 11.0 |
*Isotope Labeling | 2 | 33.0 |
Epitopes/immunology | 11 | 2.0 |
Peptide Fragments/*immunology/metabolism | 2 | 16.0 |
B-Lymphocytes/immunology | 10 | 1.0 |
Thyroglobulin/blood/*immunology | 3 | 100.0 |
Cytokines/*pharmacology | 2 | 0.0 |
Interleukin-1/pharmacology | 3 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Antigen-Antibody Complex/*immunology | 2 | 2.0 |
B-Lymphocytes/*immunology | 3 | 0.0 |
Insulin-Like Growth Factor Binding Protein 1 | 2 | 9.0 |
Adrenergic beta-Antagonists/therapeutic use | 2 | 2.0 |
Menstrual Cycle | 2 | 1.0 |
Autoantibodies/*biosynthesis | 10 | 16.0 |
Lipoproteins, HDL Cholesterol/blood/metabolism | 3 | 37.0 |
Hyperlipoproteinemia Type IV/*blood/genetics | 3 | 100.0 |
Thyroglobulin/antagonists & inhibitors | 2 | 66.0 |
Methimazole/*therapeutic use | 2 | 28.0 |
Arachidonic Acid/blood | 2 | 28.0 |
Docosahexaenoic Acids/blood | 3 | 33.0 |
Eicosapentaenoic Acid/blood | 3 | 50.0 |
Fatty Acids, Essential/*blood | 2 | 50.0 |
*Hemostasis | 2 | 1.0 |
Heat | 4 | 0.0 |
Indoles/*pharmacology | 2 | 2.0 |
Thyroglobulin/analysis/*metabolism | 2 | 100.0 |
*Eating | 4 | 6.0 |
Oleic Acids/pharmacology | 2 | 9.0 |
Obesity/blood/*genetics | 3 | 23.0 |
Triglycerides/biosynthesis/secretion | 3 | 75.0 |
Serum Albumin/metabolism | 2 | 1.0 |
Sheep | 6 | 1.0 |
*Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 15.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
*Cold | 2 | 3.0 |
Fasting/metabolism | 3 | 17.0 |
Postmenopause/physiology | 2 | 14.0 |
Homeostasis/physiology | 2 | 3.0 |
Korea | 3 | 1.0 |
Cholesterol, Dietary/administration & dosage | 4 | 14.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Thyroid Gland/radionuclide imaging | 2 | 50.0 |
Molecular Biology | 2 | 0.0 |
PrPSc Proteins | 3 | 10.0 |
Apolipoproteins B/analysis | 2 | 7.0 |
Chylomicrons/metabolism | 3 | 13.0 |
Intestinal Absorption | 2 | 1.0 |
Lipoproteins, LDL/blood/*metabolism | 2 | 13.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
Immunoglobulin G/*blood | 2 | 3.0 |
Eicosanoids/metabolism | 2 | 18.0 |
Phospholipids/*metabolism | 2 | 1.0 |
Heparin/pharmacology | 3 | 1.0 |
Mass Screening/*methods | 2 | 3.0 |
Quality of Life | 2 | 1.0 |
Cluster Analysis | 3 | 1.0 |
Fatty Acids/analysis | 4 | 13.0 |
Hypertriglyceridemia/blood/complications | 2 | 50.0 |
Plasminogen Activator Inhibitor 1/blood | 2 | 1.0 |
Hyperlipidemia/genetics | 3 | 18.0 |
Brain Mapping | 2 | 1.0 |
Enzyme Induction | 2 | 0.0 |
*Immunoenzyme Techniques | 2 | 1.0 |
DNA Probes | 3 | 0.0 |
Thyroid Gland/pathology/ultrastructure | 3 | 100.0 |
Graves' Disease/diagnosis | 2 | 50.0 |
Binding Sites, Antibody | 6 | 1.0 |
Immunoglobulin G/*immunology | 3 | 3.0 |
Immunoglobulin Idiotypes/*immunology | 3 | 7.0 |
Immunoglobulin G/immunology | 6 | 1.0 |
Thyroiditis/*immunology | 4 | 44.0 |
Thyroid Diseases/immunology | 8 | 61.0 |
Apolipoproteins A/*metabolism | 2 | 25.0 |
Recombinant Fusion Proteins/*biosynthesis/genetics | 2 | 13.0 |
Apoproteins/blood | 4 | 21.0 |
Isoproterenol/pharmacology | 2 | 1.0 |
Triglycerides/biosynthesis | 3 | 23.0 |
Antibody Formation/drug effects | 3 | 6.0 |
Pokeweed Mitogens/pharmacology | 6 | 7.0 |
Cytotoxicity Tests, Immunologic | 2 | 0.0 |
Staphylococcus aureus/immunology | 2 | 1.0 |
Thyroid Neoplasms/*blood/radionuclide imaging/surgery | 3 | 100.0 |
Calcitonin/analysis | 2 | 8.0 |
Lipoprotein Lipase/*deficiency | 2 | 18.0 |
Antibody Formation | 4 | 0.0 |
Graves' Disease/immunology | 6 | 13.0 |
Mice, Inbred BALB C/immunology | 2 | 6.0 |
Thyroid Neoplasms/*immunology | 3 | 42.0 |
Hypertrophy | 3 | 2.0 |
C-Peptide/blood | 4 | 2.0 |
Hypoglycemic Agents/*therapeutic use | 2 | 3.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Sex Hormone-Binding Globulin/analysis | 2 | 0.0 |
Immunoglobulins, Thyroid-Stimulating | 9 | 37.0 |
Coronary Disease/*blood | 5 | 7.0 |
Monocytes/immunology | 4 | 1.0 |
Hypolipoproteinemia/*blood | 2 | 9.0 |
Fatty Acids, Unsaturated/pharmacology | 2 | 3.0 |
Lipoprotein Lipase/analysis | 2 | 18.0 |
Thyroid Neoplasms/blood/*pathology | 2 | 100.0 |
Hemoglobin A, Glycosylated/*analysis | 2 | 0.0 |
Insulin/administration & dosage | 4 | 16.0 |
Diabetes Mellitus, Type 1/*blood | 4 | 2.0 |
*Physical Fitness | 2 | 5.0 |
Thyroglobulin/immunology/*metabolism | 3 | 100.0 |
Oleic Acids/*metabolism | 2 | 50.0 |
Ethinyl Estradiol/pharmacology | 3 | 11.0 |
Apolipoproteins/metabolism | 2 | 5.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood | 2 | 2.0 |
Urea/metabolism | 2 | 4.0 |
Tetradecanoylphorbol Acetate/toxicity | 2 | 16.0 |
Physical Education and Training | 3 | 12.0 |
Goats | 2 | 2.0 |
Great Britain | 2 | 0.0 |
Autoantibodies/*genetics | 2 | 13.0 |
Hyperlipoproteinemia/blood/*drug therapy | 3 | 60.0 |
Platelet Aggregation Inhibitors/pharmacology | 2 | 3.0 |
Drug Interactions | 2 | 0.0 |
Progesterone/*pharmacology | 2 | 2.0 |
Genes, Structural | 4 | 0.0 |
Thyrotropin/physiology | 2 | 22.0 |
Italy/epidemiology | 2 | 0.0 |
Thyroglobulin/analysis/*immunology | 4 | 100.0 |
Pain | 2 | 6.0 |
Smoking/epidemiology | 2 | 3.0 |
Hypertriglyceridemia/*metabolism | 3 | 25.0 |
Phospholipids/metabolism | 4 | 2.0 |
Thyroglobulin/blood/*secretion | 2 | 100.0 |
Iodine/*administration & dosage | 2 | 66.0 |
Genetic Techniques | 2 | 2.0 |
Isoelectric Focusing | 7 | 1.0 |
Growth Hormone/blood | 4 | 1.0 |
Cell Division/genetics/immunology | 2 | 7.0 |
Family Health | 2 | 0.0 |
Lipase/blood/*metabolism | 2 | 40.0 |
Pokeweed Mitogens/immunology | 2 | 15.0 |
Rats, Inbred Strains | 6 | 0.0 |
Triglycerides/analysis | 3 | 9.0 |
Hypercholesterolemia, Familial/blood/*drug therapy | 2 | 14.0 |
Anticholesteremic Agents/*administration & dosage | 2 | 20.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage | 2 | 50.0 |
Dietary Carbohydrates/*pharmacology | 5 | 22.0 |
*Insulin Infusion Systems | 2 | 4.0 |
Radionuclide Imaging | 2 | 14.0 |
Platelet Count | 2 | 0.0 |
Receptors, LH/*genetics | 2 | 18.0 |
Smoking/adverse effects/epidemiology | 2 | 33.0 |
Iodine Radioisotopes/diagnostic use/*metabolism | 2 | 100.0 |
Thyroglobulin/*analysis/immunology | 2 | 100.0 |
Hybridomas/immunology | 3 | 2.0 |
Autoimmune Diseases/*immunology | 6 | 3.0 |
*Fibrinolysis | 3 | 2.0 |
Epitopes/*immunology | 5 | 2.0 |
Macrophages/immunology | 3 | 1.0 |
Insulin/physiology | 2 | 6.0 |
Methimazole/*pharmacology | 2 | 40.0 |
Thyroid Neoplasms/*blood/radiotherapy/surgery | 2 | 100.0 |
Antithyroid Agents/*therapeutic use | 2 | 22.0 |
Microsomes/immunology | 8 | 34.0 |
Iodine/*metabolism | 6 | 42.0 |
Thyroid Diseases/*metabolism | 2 | 66.0 |
Hypertriglyceridemia/*blood/complications | 2 | 50.0 |
Metformin/*therapeutic use | 2 | 8.0 |
Rabbits/immunology | 2 | 2.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Iodoproteins/metabolism | 2 | 66.0 |
Protease Inhibitors/pharmacology | 2 | 0.0 |
Lipoproteins/*blood/drug effects | 2 | 20.0 |
Probucol/*pharmacology | 2 | 22.0 |
Arachidonic Acid | 3 | 4.0 |
Arachidonic Acids/blood | 2 | 18.0 |
Bleeding Time | 2 | 1.0 |
Linoleic Acid | 3 | 11.0 |
Linoleic Acids/blood | 2 | 22.0 |
Hypercholesterolemia, Familial/blood/drug therapy | 2 | 33.0 |
Creatine Kinase/blood | 2 | 1.0 |
Diffusion | 2 | 2.0 |
Clofibrate/*therapeutic use | 2 | 50.0 |
Exertion | 4 | 5.0 |
Palmitic Acid/blood | 2 | 100.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Antigens, Neoplasm/*analysis | 2 | 0.0 |
Apolipoprotein A-I | 12 | 10.0 |
Apolipoprotein A-II | 6 | 12.0 |
Birth Weight | 3 | 1.0 |
Immunochemistry | 4 | 1.0 |
*Iron-Binding Proteins | 2 | 5.0 |
Bone Neoplasms/blood/secondary | 3 | 50.0 |
Lung Neoplasms/blood/secondary | 3 | 75.0 |
Thyroid Neoplasms/*blood/surgery | 2 | 66.0 |
Antibody Affinity | 5 | 2.0 |
Enzyme Activation/drug effects | 3 | 0.0 |
Hybridomas/*immunology | 2 | 6.0 |
Lipase/*physiology | 2 | 25.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Platelet Aggregation/*drug effects | 2 | 1.0 |
Body Temperature | 2 | 2.0 |
Thyroiditis, Autoimmune/*immunology/pathology | 2 | 28.0 |
Receptors, Fc/*immunology | 2 | 6.0 |
Receptors, IgG | 3 | 2.0 |
Thyroid Function Tests/methods | 2 | 100.0 |
Cholesterol/blood/*metabolism | 2 | 9.0 |
Lipoproteins, LDL/blood/metabolism | 2 | 20.0 |
Triglycerides/blood/metabolism | 4 | 18.0 |
Blood Glucose | 5 | 6.0 |
Carcinoma/analysis | 2 | 25.0 |
Thyroid Neoplasms/*analysis | 4 | 66.0 |
Food, Formulated | 2 | 6.0 |
Thyroid Gland/*secretion | 3 | 100.0 |
Ultrasonography | 4 | 5.0 |
Neoplasm Recurrence, Local/blood/diagnosis | 2 | 50.0 |
Heparin/administration & dosage | 3 | 13.0 |
Thyroglobulin/*genetics/immunology | 2 | 66.0 |
Contraceptives, Oral, Combined/*pharmacology | 2 | 12.0 |
Desogestrel | 4 | 13.0 |
Pressure | 3 | 2.0 |
Thyroid Hormones/*metabolism | 2 | 6.0 |
Chondroitin/*analogs & derivatives | 2 | 40.0 |
Chondroitin Lyases/metabolism | 2 | 50.0 |
Chondroitin Sulfates/*metabolism | 2 | 14.0 |
*Autoantibodies | 2 | 12.0 |
Immunoglobulin G/metabolism | 3 | 1.0 |
Thyroid Gland/drug effects/metabolism | 2 | 25.0 |
Iodine Radioisotopes/diagnostic use/*therapeutic use | 3 | 100.0 |
Muscles/enzymology/*metabolism | 2 | 40.0 |
Antibodies, Monoclonal/*biosynthesis/immunology | 2 | 7.0 |
Carcinoembryonic Antigen/analysis | 3 | 2.0 |
Epitopes/*analysis | 8 | 5.0 |
Triiodothyronine/immunology | 4 | 66.0 |
Microsomes/*immunology | 3 | 20.0 |
Carotenoids/administration & dosage/*blood | 2 | 100.0 |
Retinoids/blood | 2 | 50.0 |
beta Carotene | 2 | 12.0 |
Endoplasmic Reticulum/ultrastructure | 4 | 30.0 |
Immunoelectrophoresis | 3 | 1.0 |
Albumins/metabolism | 2 | 1.0 |
*Protein-Serine-Threonine Kinases | 2 | 0.0 |
*Physical Endurance | 2 | 4.0 |
*Fasting | 3 | 12.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Thyroxine/metabolism | 4 | 16.0 |
Dietary Carbohydrates/metabolism | 2 | 16.0 |
*Diabetic Diet | 2 | 9.0 |
Triiodothyronine/metabolism | 2 | 5.0 |
Thyroglobulin/*immunology/isolation & purification | 3 | 100.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Multicenter Studies | 2 | 1.0 |
Procetofen/adverse effects/*therapeutic use | 2 | 66.0 |
Receptors, Cytoplasmic and Nuclear/genetics | 2 | 5.0 |
Autoradiography | 2 | 0.0 |
DNA Restriction Enzymes | 3 | 0.0 |
Autoantibodies/*secretion | 2 | 100.0 |
Cell Transformation, Viral | 2 | 0.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Capsules | 2 | 4.0 |
Hyperlipoproteinemia Type IV/*blood | 3 | 25.0 |
Hypothyroidism/*blood | 2 | 7.0 |
Diabetes Mellitus, Type 1/*blood/drug therapy | 2 | 5.0 |
Thyroid Neoplasms/immunology | 3 | 60.0 |
Thyroid Neoplasms/*analysis/pathology | 2 | 100.0 |
Levonorgestrel | 2 | 6.0 |
Tumor Necrosis Factor-alpha/*metabolism | 2 | 0.0 |
Infusions, Parenteral | 2 | 1.0 |
Goiter/congenital | 2 | 66.0 |
*Lymphocyte Activation | 3 | 0.0 |
Fat Emulsions, Intravenous/*metabolism | 3 | 75.0 |
*Parenteral Nutrition | 2 | 10.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*metabolism | 2 | 3.0 |
Norpregnenes/*pharmacology | 2 | 20.0 |
Karyotyping | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Radioimmunoassay/methods | 9 | 5.0 |
Thyroid Neoplasms/*blood/diagnosis | 3 | 75.0 |
Clofibric Acid/therapeutic use | 2 | 100.0 |
Delayed-Action Preparations | 2 | 1.0 |
T-Lymphocytes/classification/*immunology | 3 | 4.0 |
Chemistry | 2 | 0.0 |
Chickens | 3 | 0.0 |
Thyroid Diseases/*blood | 2 | 22.0 |
Twins, Monozygotic | 2 | 2.0 |
Antibodies/analysis | 3 | 2.0 |
Thyroid Gland/*immunology/pathology | 2 | 28.0 |
Kidney Failure, Chronic/*blood/therapy | 2 | 3.0 |
Commonwealth of Independent States | 2 | 33.0 |
Health Services/*utilization | 2 | 16.0 |
Health Services Research | 2 | 11.0 |
Patient Acceptance of Health Care | 2 | 8.0 |
Lymphocytes/*immunology | 4 | 0.0 |
Africa, Northern/ethnology | 2 | 13.0 |
Europe/ethnology | 2 | 2.0 |
Israel | 2 | 1.0 |
Respiratory Distress Syndrome, Newborn/*blood | 2 | 33.0 |
Infant, Small for Gestational Age | 2 | 10.0 |
Adenocarcinoma/immunology | 2 | 4.0 |
Hyperthyroidism/*blood | 2 | 10.0 |
Oxprenolol/pharmacology | 2 | 66.0 |
Antibodies, Monoclonal/*biosynthesis | 3 | 8.0 |
Iodized Oil/*therapeutic use | 2 | 66.0 |
Cell Separation/methods | 2 | 1.0 |
Hypothyroidism/congenital | 2 | 100.0 |
Immunoglobulin Idiotypes/*analysis/immunology | 2 | 100.0 |
Goiter, Nodular/*metabolism | 2 | 66.0 |
Methods | 4 | 1.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
Phospholipids/analysis | 2 | 5.0 |
Thyroid Gland/abnormalities | 2 | 28.0 |
Lipids/biosynthesis | 2 | 10.0 |
Antigens/*immunology | 2 | 2.0 |
Fetal Blood/*analysis | 4 | 11.0 |
Hyperlipoproteinemia/*etiology | 2 | 50.0 |
Phenols/*therapeutic use | 2 | 100.0 |
Adipose Tissue/enzymology | 3 | 10.0 |
Dietary Carbohydrates/administration & dosage | 2 | 7.0 |
Muscles/enzymology | 3 | 5.0 |
Lipoproteins, VLDL Cholesterol | 2 | 15.0 |
Bone Neoplasms/secondary | 3 | 6.0 |
Receptors, Thyrotropin | 2 | 50.0 |
Thyrotropin/*metabolism | 2 | 9.0 |
Chromosome Banding | 2 | 0.0 |
Thyroglobulin/*isolation & purification | 3 | 100.0 |
Thyroid Gland/*analysis | 2 | 33.0 |
Glycerol/*metabolism | 2 | 18.0 |
*Oncogenes | 2 | 0.0 |
Carcinoma/*blood/pathology | 2 | 40.0 |
Thyroid Neoplasms/*blood/pathology | 3 | 50.0 |
*Physical Education and Training | 2 | 3.0 |
Fatty Acids/*pharmacology | 2 | 7.0 |
Thyroid Neoplasms/*therapy | 2 | 100.0 |
Fatty Acids, Nonesterified/metabolism | 2 | 6.0 |
Hypercholesterolemia/blood | 3 | 15.0 |
Apolipoproteins B | 4 | 9.0 |
Phytohemagglutinins/pharmacology | 2 | 0.0 |
Rosette Formation | 4 | 1.0 |
Lipoproteins, HDL Cholesterol | 7 | 15.0 |
Adsorption | 3 | 1.0 |
Hyperthyroidism/blood | 2 | 10.0 |
Cytotoxicity, Immunologic/*drug effects | 2 | 2.0 |
Coated Pits, Cell-Membrane/ultrastructure | 2 | 66.0 |
*Endocytosis | 2 | 1.0 |
Goiter, Nodular/*metabolism/pathology | 2 | 66.0 |
Microvilli/ultrastructure | 2 | 13.0 |
Pseudopodia/ultrastructure | 2 | 50.0 |
Thyroid Gland/*metabolism/ultrastructure | 2 | 50.0 |
Coronary Disease/physiopathology | 2 | 12.0 |
Lipoproteins, LDL Cholesterol | 3 | 12.0 |
Hyperthyroidism/diagnosis | 3 | 33.0 |
Hypothyroidism/diagnosis | 2 | 22.0 |
Thyroiditis/diagnosis | 3 | 50.0 |
Antibody-Dependent Cell Cytotoxicity | 2 | 2.0 |
Antibody-Producing Cells/immunology | 2 | 8.0 |
Hemolytic Plaque Technique | 2 | 3.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Immunoglobulin G | 3 | 2.0 |
Precipitation | 2 | 1.0 |
Rheumatic Diseases/*immunology | 2 | 12.0 |
Synovial Fluid/cytology/immunology | 2 | 10.0 |
Propylthiouracil/therapeutic use | 2 | 28.0 |
Albumins/analysis | 2 | 5.0 |
Fat Emulsions, Intravenous/diagnostic use | 2 | 66.0 |
*Apolipoproteins | 4 | 12.0 |
Concanavalin A/pharmacology | 4 | 1.0 |
Autoantibodies | 2 | 6.0 |
Goiter/enzymology | 2 | 50.0 |
Jejunum/*metabolism/ultrastructure | 2 | 100.0 |
Linolenic Acids/*metabolism | 2 | 66.0 |
*Infant, Newborn | 2 | 4.0 |
Nicotinic Acids/*therapeutic use | 2 | 40.0 |
Immunoglobulins, Fc/analysis | 2 | 33.0 |
*Antibody-Dependent Cell Cytotoxicity | 2 | 4.0 |
Arteriosclerosis/*epidemiology | 2 | 100.0 |
Carcinoma, Papillary/blood/*diagnosis/therapy | 2 | 100.0 |
Thyroid Neoplasms/blood/*diagnosis/therapy | 2 | 100.0 |
Carcinoma, Papillary/*blood/therapy | 2 | 100.0 |
Ethnic Groups | 2 | 0.0 |
Thyroid Neoplasms/blood/radionuclide imaging/*radiotherapy | 2 | 100.0 |
Hypothyroidism/blood | 2 | 15.0 |
*Neoplasm Metastasis | 2 | 2.0 |
Hyperlipidemia/drug therapy | 3 | 23.0 |
Triglycerides/*blood/physiology | 2 | 100.0 |
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage | 2 | 22.0 |
Cholesterol Esters/biosynthesis | 2 | 14.0 |
*Flavanones | 2 | 8.0 |
Flavonoids/*pharmacology | 2 | 2.0 |
Acetylcholine/pharmacology | 2 | 2.0 |
Fatty Acids, Monounsaturated/administration & dosage | 2 | 66.0 |
Liver/metabolism/*pathology | 2 | 10.0 |
Hepatoblastoma | 2 | 11.0 |
Liver Neoplasms | 2 | 0.0 |
Lipoproteins, HDL/blood/*classification | 2 | 100.0 |
Lipoproteins, HDL Cholesterol/analysis/genetics | 2 | 100.0 |
Environment | 2 | 2.0 |
